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Rheumatic heart disease: prevalence, diagnostic tests, and burden of 
disease in New Caledonia 
 
Cardiopathie Rhumatismale: Prévalence, méthodes diagnostiques, morbidité et mortalité 
attribuables en Nouvelle Calédonie 
 
Abstract 
 
Rheumatic Heart Disease (RHD) is the leading cause of acquired heart disease in children and 
young adults worldwide, with significant associated morbidity and mortality. Early secondary 
prophylaxis may retard the deleterious progression from its antecedent, acute rheumatic fever 
to permanent heart valve damage, and thus several echocardiographic screening programmes 
to detect asymptomatic RHD and institute early prophylaxis have been conducted. While 
effective interventions are available for ameliorating the effects of RHD, research on their use 
in different settings is scant. Key questions remain regarding the natural history of 
asymptomatic RHD and the optimal method for early detection. In addition, there is a lack of 
contemporary estimates of mortality and morbidity among the symptomatic population. 
The primary purpose of the thesis was to determine the outcomes of asymptomatic and 
symptomatic RHD. More specifically, this thesis focuses on the outcomes of asymptomatic 
RHD diagnosed by means of systematic echocardiography-based screening, and assesses a 
simplified echo-based protocol for screening in schoolchildren. Population-based and 
hospital-based estimates of disease burden are provided in this work. Finally, outcomes of 
symptomatic RHD are depicted in a captive population and factors associated with poor 
outcomes identified in patients with newly diagnosed RHD.  
This thesis has five key findings. Firstly, research methods used for echocardiography-based 
screening may not be readily translated into public health policies. Secondly, asymptomatic 
echocardiography-screened RHD has a variable natural history that ranges from regression to 
a normal state, to persistence of mild disease in the majority of cases. Also, a single screening 
point in childhood among populations at risk may prove insufficient. Thirdly, a focused hand-
held echocardiography protocol shows promising levels of sensitivity and specificity for 
detecting subclinical RHD by non-experts. Fourthly, hospital-based prevalence estimates are 
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in keeping with population-based data and confirm the high burden of RHD in New 
Caledonia. Symptomatic RHD is often revealed by its complications. Finally, the survival rate 
is 96% at 8 years and the incidence of major cardiovascular events is of 59 per 1,000 patients 
year in the subset of patients with newly diagnosed RHD and no complications at entry. 
Factors associated with poor outcomes include the severity of heart valve disease at diagnosis 
and discontinuation of secondary prophylaxis. 
 
The findings encapsulated in this thesis add to the knowledge of the burden of this disease by 
providing prevalence figures in the population and from a hospital-based cohort. These 
studies may have important implications for policy, practice and research related to the 
management of asymptomatic and symptomatic RHD. 
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1. Introduction 
 
Rheumatic heart disease (RHD) remains the leading acquired heart disease in the young 
worldwide.1 Although prevalence, morbidity and mortality have been recently assessed by the 
Global Burden of Disease study, the data these estimates are based on are scant.2, 3 Rheumatic 
heart disease, a disease of poverty, has almost disappeared from wealthy countries, its burden 
remains a major challenge in the developing world.4, 5  According to the 2008 Population 
Reference Bureau’s estimates, approximately 80 to 85% of the children under 15 years of age 
(around 2 billion) live in areas endemic for RHD and are potentially at risk of developing the 
disease.6 Retrospective studies show that RHD is associated with high mortality and 
substantial morbidity due to sequel such as congestive heart failure (CHF), stroke and 
infective endocarditis (IE).7, 8 Yet, contemporary estimates of the burden of disease, especially 
from different areas where this disease is endemic are scant and largely biased. 
Rheumatic heart disease is the result of valvular damage caused by an exaggerated immune 
response to group A streptococcal (GAS) infections, usually during infancy and childhood.1, 9, 
10 Acute rheumatic fever (ARF) usually occurs 3 weeks after GAS pharyngitis and may 
involve joint, skin, brain and heart.11  One-third to half the patients with a first ARF episode 
present with carditis, with cardiac inflammation mainly involving the valvular 
endocardium.12-15 Although the initial attack can lead to severe valvular disease, RHD most 
often results from cumulative valve damage due to recurrent ARF episodes and thus RHD 
may be of insidious onset.5, 16 However, if diagnosed early enough with timeous institution of 
secondary prophylaxis, the deleterious progression to permanent heart valve damage due to 
recurrent episodes of ARF need not occur. The concept of early identification of silent 
rheumatic “minimal” valve lesions has emerged in recent years, because of echocardiography-
based detection.17, 18 This approach was first developed for the diagnosis of subclinical 
carditis in the setting of ARF.19, 20 This argument has led to the launch of a multitude of 
echocardiographic screening studies to document the prevalence of subclinical disease and to 
institute early therapy in affected individuals.19, 21 There are, however, several unanswered 
questions in regards to echocardiography-based screening for RHD.  Only short-term studies 
exist with regard to the use of screening to detect subclinical RHD therefore the prognosis of 
subclinical RHD remains unknown. Also, screening methods that have been used for research 
purposes may not be applicable in most settings where RHD remains endemic due to the high 
cost of equipment and need of experienced users and readers. 
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This thesis focuses on exploring the outcomes of asymptomatic and symptomatic RHD within 
the context of increasing numbers of screening programmes and ways for simplified 
echocardiography-based screening. In this introduction is summarized the current knowledge 
related to disease estimates for RHD, the morbidity and mortality associated with RHD, and 
screening methods for early detection of RHD.
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1.1. The epidemiology of Rheumatic Heart Disease 
 
Improved living conditions, penicillin use, and access to medical care have radically changed 
the epidemiology of ARF and RHD in high-income settings.5 Nevertheless, both prevail in 
developing nations and some unprivileged, mainly indigenous, populations in affluent 
countries.21-24 In 2005, a summary report, commissioned by the WHO, was released on the 
global burden of Group A streptococcal disease; it encapsulated population-based data 
relating to ARF and RHD that had been published between 1985 and 2005.5, 25 The overall 
burden of RHD was estimated to be 15-20 million prevalent cases, with 282,000 new cases 
and over 233,000 deaths per year (Figure 1.1). Difficulties with such estimates are mainly 
related to the lack of comprehensive disease registries, passive survey systems and 
underreporting of acute and chronic cases.22, 26  
 
 
Figure 1.1. Prevalence of rheumatic heart disease.5  
 
The recently published Global Burden of Disease 2010 Study, reported 345,100 deaths due to 
RHD in 2010, representing a 25.4% reduction compared with those occurring in 1990, with an 
age-standardized death rate of 5.2 per 100,000. This represents a 53.1% reduction in the death 
rate, when compared with the number of deaths that occurred in 1990.2 Lozano reported that 
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the number of years lived with disability due to RHD was estimated at 1,430 in 2010 (95% 
confidence intervals [CI] 944 to 2067) worldwide, a figure that represents up to one fourth of 
all neoplasms.27 It is necessary to re-analyze these data, however, due to uncertainties 
regarding their accuracy. Of particular concern were the clear inconsistencies relating to the 
epidemiology of the disease, the age groups that are most at risk, and the extreme paucity of 
incident and mortality data from developing countries. Moreover, a recent report from the 
Northern Territories in Australia reported little evidence of a decline in the incidence of ARF 
or RHD.28 
Inter-regional variability is to be stressed in terms of RHD related mortality. In areas of poor 
or no medical attention, the natural course of the disease prevails because of poor access to 
treatment, as cardiac interventions in sub-Saharan Africa (Figure 1.2).29-31 Mortality rates in 
these areas may be as high as 20% at 6 years follow-up, as illustrated in a Nigerian paediatric 
cohort study,32 or of 12.5% annually, as documented in rural Ethiopia.8 These are in contrast 
with more recent mortality reported in Australia where the survival rates are of 96.1% at 5 
years among Indigenous Australians.28 One of the objectives of this thesis is to provide 
accurate figures in New Caledonia thereby adding to the knowledge on the burden of RHD.  
 
Figure 1.2. Countries with established cardiac surgery programmes in Africa. 29 
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1.2. Rationale, feasibility, means and controversies regarding echo-based screening 
 
The rationale for active surveillance is not only to provide the most accurate epidemiological 
data of the disease but also to offer early treatment to those affected, especially the large 
proportion of asymptomatic patients who may subsequently develop advanced RHD. The 
Council of Europe and WHO recommend screening programmes in the setting of preventable 
diseases.33, 34 In most countries, the majority of children are readily accessible through school 
screening surveys. Under the auspices of the WHO, approximately 15 million children were 
screened for RHD across 16 countries.35 Unfortunately the outbreak of HIV and its 
devastating consequences diverted local priorities in many developing nations and led to 
discontinuation of funding for many RHD programs.  
The first large surveys were based on clinical examination.36-38 However, cardiac auscultation 
lacks sensitivity. Small regurgitant volumes, especially mitral regurgitation posteriorly 
directed jets, may simply not be audible to the human ear. Cardiac examination requires a 
quiet environment and is time consuming, and to distinguish functional from organic 
murmurs is far more challenging in clinical practice than in theory.39, 40 Functional murmurs 
are very common among children, especially in the presence of fever or anaemia, as may be 
the case during malaria or sickle cell disease. Auscultation skills require specific training that 
seemingly are no longer mandatory in medical schools in wealthy countries, where cardiac 
imaging is readily available.41 In a three-step screening programme conducted in Tonga, 
junior and experienced physicians auscultation skills were compared.20 Even though the more 
experienced physician had a better ability to detect pathological murmurs, at least half the 
cases of RHD were missed by auscultation alone.20 
In addition to the intrinsic limitations of auscultation in detecting valvular disease, cardiac 
examination may not uniformly occur during follow-up after clinical carditis,42, 43, and even if 
practised, most patients with echo-detected RHD have normal findings on auscultation.15, 43-45 
Taken together, these studies demonstrate that clinical examination alone is unable to detect 
the majority of children with RHD.46 
 
Echocardiography as a tool to detect subclinical carditis has emerged after the publications of 
studies comparing RHD prevalence assessed by ultrasounds versus cardiac auscultation 
(Figure 1.3).19, 20, 47-52 Recently reviewed in a meta-analysis by Rothenbüler and colleagues, 
the pooled prevalence of rheumatic heart disease detected by cardiac auscultation was 2.9 per 
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1000 people (95% CI 1.7–5.0) and by echocardiography it was 12.9 per 1000 people (95% CI 
8.9–18.6).21  
 
 
Figure 1.3. Screening using auscultation versus echocardiography.1 
 
 
The interregional variation of RHD prevalence may be due to true differences in the burden of 
the disease, the sensitivity of the criteria used, or the combination of both.  In this context, the 
World Heart Federation (WHF) released guidelines in 2012 for the diagnosis of RHD in order 
to standardize echocardiography criteria (Table 2.1.).53 These criteria consolidated 
international expert opinion by combining Doppler and morphological features of the left-
sided valves. The advent of echo-based screening for RHD led to a new model of the 
epidemiology of RHD. This includes asymptomatic RHD and symptomatic RHD as a 
continuum  (Figure 1.4). 
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World Heart Federation’s Criteria for Echocardiographic Diagnosis of Rheumatic 
Heart Disease 
 
Echo criteria for children ≤ 20 years of age 
 
Definite RHD (either A, B, C or D): 
Pathological MR and at least two morphological features of RHD of the MV 
MS mean gradient ≥ to 4 mmHg (NB – exclude congenital MV anomalies) 
Pathological AR and at least two morphological features of RHD of the AV  
Borderline disease of both the aortic and mitral valves 
 
Borderline RHD (either A, B or C): 
At least two morphological features of RHD of the MV without pathological MR or MS 
Pathological MR  
Pathological AR  
 
Normal Echocardiographic findings (all A, B and C); 
MR that does not meet all four Doppler criteria (Physiological MR) 
AR that does not meet all four Doppler criteria (Physiological AR) 
An isolated morphological feature of RHD of the MV or the AV (e.g. vulvar thickening) without any 
associated pathological stenosis or regurgitation 
 
 
Table 2.1. World Heart Federation Diagnostic criteria for RHD under 20 years of age. See full 
article for explanatory notes and caveats.53 
Pathological Regurgitation 
Mitral Regurgitation 
(all four Doppler criteria must be met) 
Aortic Regurgitation 
(all four Doppler criteria must be met) 
1.  Seen in 2 views 1.  Seen in 2 views 
2.  In at least one view jet length ≥ 2 cm 2.  In at least one view jet length ≥ 1 cm 
3.  Peak velocity ≥ 3m/sec 3.  Peak velocity ≥ 3m/sec 
4.  Pansystolic jet for at least one envelope 4.  Pandiastolic jet for at least one envelope 
Morphological features of RHD 
Mitral Valve Aortic Valve 
1.  AMVL thickening ≥ 3mm  1.  Irregular or focal thickening 
2.  Chordal thickening  2.  Coaptation defect 
3.  Restricted leaflet motion  3.  Restricted leaflet motion 
4.  Excessive leaflet tip motion during systole  4.  Prolapse 
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Figure 1.4. Model incorporating asymptomatic and symptomatic disease.54 
 
 
Although echocardiography detects 3 to 10 times more valvular lesions than auscultation, 
several issues need to be addressed before its implementation. Screening for asymptomatic 
RHD has given rise to much debate, including around the prognosis of subclinical RHD, the 
criteria chosen to define RHD, and the impact on public health policies.55, 56 These debates 
relate to the ability of developing countries to manage the large numbers of patients who will 
be detected by means of echocardiography, the appropriate treatment for these patients and 
the cost-effectiveness of screening for RHD. 
The natural history of subclinical RHD in asymptomatic populations without a previous 
history of ARF is not well characterized. Four studies have reported on the short-term 
progress of subclinical RHD detected by echocardiography. These studies lacked power to 
assess clinical endpoints and all focused on the persistence of echocardiographic lesions.47, 50, 
57, 58 
The WHF criteria are based on the best available evidence, its use requires high-end 
echocardiography machines, experienced users and readers. These technical, and financial, 
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aspects may prevent use of WHF criteria in low-income settings. Simpler ways to detect RHD 
need to be validated for screening to be implemented as a public health policy.  
 
In this thesis two distinct studies assess the burden of RHD in New Caledonia by means of a 
population-based echo-screening programme and a hospital-based cohort of symptomatic 
RHD patients. In addition, outcomes of children with asymptomatic RHD and a focused 
cardiac ultrasound approach are also examined.
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2. Methods of the thesis 
 
2.1. Settings  
2.1.1. New Caledonia: geographic, social and economic features 
 
New Caledonia is a special collectivity of France located in the southwest Pacific 
Ocean, divided into three Provinces (Northern, Southern and Loyalty Islands 
Provinces). The country population was 260 000 according to the 2014 census, with 
43,091 children aged 5-14 years (17.5%), among which a majority (44.6%) were 
indigenous Melanesian, followed by Caucasian (22.5%), Polynesian (10.9%), of 
mixed origins (13.0%), Asian (1.4%), and other (7.3%). The distribution of ethnic 
groups is uneven across the archipelago with a majority of indigenous Melanesians 
residing in the Northern and Loyalty Provinces. Life expectancy is 76 years for those 
born in 2010. Primary school is universal and mandatory, and attendance is estimated 
at 86% for primary and pre-primary schools.59 
 
 
 
Figure 2.1. World map. 
 
Although classified as a high-income country according to a GDP per capita of 
35,298 USD in 2010 (rank 33),60 with a rapidly growing market economy, major 
socio-economic disparities prevail within the New Caledonian society. The annual 
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income per annum is two fold higher in the Southern Province where a majority of the 
population from European descent lives compared to the other two Provinces (mainly 
populated by indigenous Melanesians).61 
 
 
   Figure 2.2. Map of New Caledonia. 
 
2.1.2. The New Caledonian healthcare system 
 
The healthcare system is similar to that of mainland France. There is universal 
healthcare coverage through various social security systems according to the level of 
income of the patient. Diseases such as RHD are universally covered with either no 
charges to the patient or 100% reimbursement of investigations and treatments related 
to the condition. 
Primary care centres are widespread and cover the entire country. The density of 
medical Doctors is 223 per 100 000 inhabitants, including general practitioners and 
specialists. Theses figures vary however according to the region with 274 practioners 
per 100 000 in the South, 96 per 100 000 in the North and 80 per 100 000 on the 
Loyalty Islands.62 
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Figure 2.3. Distribution of primary healthcare centres. Dispensaire stands for primary 
care centre; Pharmacie, stands for pharmacy.  
 
Prevention of non-communicable diseases is led by the Agence Sanitaire et Sociale de 
Nouvelle Calédonie (ASS-NC). This institution has set up a programme of RHD 
control including awareness campaigns among healthcare workers and the population, 
recommendations for sore throat detection and treatment, notification of ARF, and a 
National Register of Secondary Prophylaxis.  
As in mainland France, the healthcare system is dual, public and private, the latter 
being funded by the social security that decides the fares. The Centre Hospitalier 
Territorial de Nouvelle Calédonie (CHT) is the main hospital for the entire country, 
the only to provide specialist care including cardiology, infectious diseases, 
neurology, paediatrics and intensive care. 
Heart valve interventions were not available in New Caledonia until 2013. Patients 
are referred overseas for cardiac surgery and most percutaneous valve procedures. 
The Département des Evacuations Sanitaires (EVASAN) coordinates and funds all 
overseas referrals. A national mortality database is held by the Departement des 
Affaires Sanitaires et Sociales (DASS). 
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2.2. Study 1. Lessons from the first nationwide echocardiography-based 
screening programme for Rheumatic Heart Disease and outcomes of 
asymptomatic Rheumatic Heart Disease 
 
The New Caledonian government declared RHD a public health priority in 2007. The 
political will to eradicate the condition was driven by the ASS-NC. An 
echocardiography-based screening program aiming at all 4th graders (i.e., aged 9-10 
years) in primary schools was launched from February 2008 after a pilot study carried 
out in 2007. This survey was meant to be part of a public health prevention program. 
All schools in the country (public and private) were included in the survey. The aim 
was to screen all 4th graders once a year, every year. After obtaining the 
authorizations of the Ministry of Education, all schools were notified of the date of 
screening. Visits by healthcare workers were organized prior to the survey in order to 
inform the children. Parents or guardians were asked to provide written informed 
consent. The screening included echocardiography, collection of sociodemographic 
characteristics (sex, date of birth and declared ethnicity), and past history of ARF or 
known RHD. No second visits were scheduled. 
The diagnostic echocardiography protocol comprised two steps. Cardiologists from 
New Caledonia constituted a working group, acquired and interpreted the 
echocardiograms. A standardized echocardiography was performed at school in all 
children who accepted to participate with a written consent from one of the parents. 
When an abnormality was suspected, children were invited to attend a second 
examination by an experienced cardiologist at a free of charge clinic either in Nouméa 
or during outreach clinics in remote locations. Rheumatic heart disease was diagnosed 
only on the second scan according to predefined criteria agreed among Cardiologists 
participating in the programme that is detailed below (Section 2.2.4).63  
All children diagnosed with RHD were offered free of charge secondary prophylaxis 
and yearly follow-up echocardiograms, and entered the National Register of 
Secondary Prophylaxis conducted by the ASS-NC. Children with incidental findings 
of congenital heart disease (CHD) were referred to a specialist clinic and offered 
intervention accordingly. 
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2.2.1. Aims 
The aims of this study were threefold: 
• To assess the first nationwide echocardiography-based screening programme 
for RHD in terms of completeness  
• To estimate RHD prevalence in schoolchildren in New Caledonia 
• To assess the outcomes of asymptomatic schoolchildren with and with no 
features of RHD on echocardiogram; secondary objectives included the 
identification of factors associated with the persistence or the progression of 
RHD. 
 
2.2.2. Study design 
This is a retrospective cohort study driven from the yearly RHD echocardiography 
screening campaigns from February 2008 to December 2011. Cross-sectional follow-
up was carried out in 2012. 
 
Inclusion criteria: diagnosis of RHD based on echocardiography following pre-
specified criteria detailed below and controls with no RHD at baseline. 
Exclusion criteria: subsequent diagnosis of congenital heart disease by an expert. 
Data collected: socio-demographic characteristics; heart valve pattern and severity at 
diagnosis; clinical and echocardiographic measurements at follow-up. 
 
2.2.3. Participants 
All children with features of RHD on systematic echocardiography and a subset of 
matched controls with normal echocardiograms at baseline were eligible for 
enrolment. Controls attended the same class as cases and were matched according to 
ethnicity. Matching for same sex was made difficult in remote schools with a limited 
number of students per class. Two controls per case were aimed at. 
 
2.2.4. Echocardiography protocols 
Echocardiography for RHD diagnosis 
The acquisition of the initial echocardiograms followed contemporary guidelines and 
included standard parasternal long and short axis views, apical four, two and three 
	  
 
	   29	  
chamber views. Acquisition was performed in grey-scale and Colour Doppler. Images 
were not systematically recorded for review.63 
The initial criteria had been established by a group of senior cardiologists who took 
part in the RHD programme. These were derived from the WHO criteria and enriched 
of morphological criteria according to the publication by Marijon et al. These criteria 
included a combination of at least two morphological changes of the mitral valve and 
mitral regurgitation, aortic regurgitation or mitral stenosis and are detailed in Table 
2.2. 
 
Diagnosis of:  New Caledonia criteria WHF criteria 
Mitral stenosis • Mean gradient ≥4mmHg 
Or 
• Surface area<1.5cm2 
• Mean gradient ≥4mmHg 
 
Pathological mitral 
regurgitation 
• Seen in two views 
• Jet length ≥2 cm 
• Pan-systolic jet 
• Mosaic colour jet with 
velocity ≥ 2.5 m/s 
• Seen in two views 
• Jet length ≥2 cm 
• Pan-systolic jet  
• Velocity ≥3 m/s for one 
complete envelope 
Pathological aortic 
regurgitation 
•  Jet length ≥1 cm 
• Pan-diastolic jet 
• Mosaic colour jet with 
velocity ≥ 2.5 m/s 
• Jet length ≥1 cm 
• Pan-diastolic jet  
• Velocity ≥3 m/s  
• Seen in two views 
Morphological features of the 
MV 
• AMVL thickening >5mm 
• Chordal thickening 
• Abnormal mobility of 
valve leaflets 
• ‘Dog leg’ anterior mitral 
valve leaflet deformity 
• AMVL thickening ≥3mm 
• Chordal thickening 
• Restricted leaflet motion 
• Excessive leaflet tip 
motion during systole 
Morphological features of the 
AV 
- • Irregular or focal 
thickening 
• Coaptation defect 
• Restricted leaflet motion 
• Prolapse 
Table 2.2. Comparison between the New Caledonian and the WHF criteria  
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Echocardiography protocol at follow-up 
Follow-up echocardiograms were performed following a standardized protocol using 
a portable high-end machine (Vivid I, GE®) with a 1.5-3.6-MHz probe. Frame rates 
ranged from 25-35 Hz for black-and-white imaging and from 12-18 Hz for colour 
Doppler. Parasternal long axis and parasternal short axis, apical four chambers, two 
chamber and three chamber, and subcostal views were acquired and settings 
optimized according to the WHF recommendations: grey scale without harmonics 
were recorded in the parasternal long axis view for subsequent measurements of the 
anterior mitral leaflet, colour Doppler was used in all views, continuous wave 
Doppler was applied to systematically measure the mean trans-mitral gradient. 
Echocardiograms were performed either at the ASS-NC, Nouméa, or at outreach 
clinics in primary health centres by a single operator (the PhD candidate). Rheumatic 
heart disease diagnosis was based on the WHF criteria following a blinded review of 
all scans by the PhD candidate using EchoPac® software (GE®) (Table 2.1.).53  
 
2.2.5. Data collection and outcomes 
Data collection 
For each participant, the following data were collected: demographics (age, sex), 
place of residence (Province, village), ethnicity, number of siblings, maternal 
employment, maternal education, housing, number of people living in the household, 
number of bedrooms, usual mode of transport (car vs. no car), whether lived over a 
year away from home (either in boarding schools or with other members of the 
extended family).  
Data on treatment included secondary prophylaxis and its modalities: date of start; 
drug used (benzathine penicillin G or oral treatment); and periodicity of penicillin 
injections when applicable. 
 
Outcomes 
Participants were classified as having "definite" RHD, "borderline" RHD or no 
RHD.53  Persistence of RHD was assessed according to the WHF criteria, including 
"definite" and "borderline" cases on echocardiogram. Progression of valve disease 
followed a pre-specified algorithm. Definition of stable valve disease included: 
unchanged grade of severity of single or multiple valve disease. Definition of 
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progression of valve disease was based either on the increased grade of isolated valve 
disease (e.g., mitral regurgitation previously grade 1/4 becoming grade ≥2/4 at 
follow-up) and/or newly diagnosed mitral regurgitation, aortic regurgitation and/or 
mitral stenosis. 
 Clinical endpoints included: a heart murmur at the follow-up clinic 
(auscultation was performed by the PhD candidate before the echocardiogram); ARF 
as per the regional guidelines,64 and/or RHD-related complications (cardiovascular 
death, heart failure, embolism, infective endocarditis, heart valve intervention using 
percutaneous approach or surgery). Finally, vital status and cause of death were 
checked in the national DASS register on August 1st 2013 for all eligible participants. 
Hospital admission to CHT was also checked for potential participants lost to follow-
up. 
 
2.2.6. Bias 
The work presented here yields a number of biases. Estimation of prevalence was 
likely to be conservative given the absence of scheduled new visits for absentees the 
day of the survey. The criteria for the diagnosis of RHD varied throughout the study. 
The initial recordings had not been kept at the ASS-NC therefore cases could not be 
reclassified according to WHF criteria published in 2012 (i.e., 4 years after the start of 
the survey). Similarly, normal echocardiograms at baseline could not be reviewed 
therefore children diagnosed with initially normal examinations may have had some 
minor abnormalities. At follow-up clinical events were collected retrospectively with 
a risk of memory bias. Finally, admission to the single paediatric facility (CHT) and 
death could be checked on but severe heart valve disease could not be ruled out in 
those lost to follow-up. 
  
2.2.7. Statistical methods 
All participants’ characteristics were described as median [IQR], mean [SD] or 
proportions, as appropriate. Prevalence estimates were computed.  Categorical 
variables were compared using chi-square test or Fisher’s exact test, and continuous 
variables using Student t-test or Wilcoxon rank sum test, as appropriate. As a 
supplementary analysis, odds ratio (OR) and relative risks (RR) for diagnosis of RHD 
at follow-up and their 95% Confidence Intervals were calculated, stratified for year of 
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diagnosis (chi-square of Mantel Haentzel). A two-sided P value of less than 0.05 was 
considered to indicate statistical significance. Patients lost to follow-up were not 
included in the analysis. All data were analysed with the use of Statistical Analysis 
System software (version 9.3).  
 
2.2.8. Ethics 
Ethical clearance was granted from the Bordeaux and French Overseas Protection 
Committee and the French Institute of Medical Research and Health. The study 
complies with the declaration of Helsinki. All children and their parents/guardians 
gave informed consent. 
 
 
2.3. Study 2. Screening for Rheumatic Heart Disease: Evaluation of a Focused 
Cardiac Ultrasound (FCU) Approach 
 
2.3.1. Aims 
The objective was to compare a FCU approach to the reference approach for the 
diagnosis of RHD. The FCU approach includes the combination of: (i) a pocket-size 
echocardiography machine, (ii) non-expert staff; and (iii) a simplified set of 
echocardiographic criteria. 
 
The study comprises two parts with different objectives: 
Part 1: to assess different diagnostic criteria directly on the pocket-echocardiography 
devices compared to reference WHF criteria in a selected population (high RHD 
prevalence). 
Part 2: to test the FCU approach (including the simplified criteria driven from Part 1) 
in school-children (lower prevalence, real conditions) compared to the reference 
approach recommended by the WHF. 
  
2.3.2. Study design 
This prospective imaging study comprises two parts. We first tested different set of 
echocardiographic criteria for RHD to be used for FCU among selected children with 
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and without RHD in March 2013 (Part 1 of the study). We then prospectively 
evaluated the feasibility and performance of a FCU approach among a population of 
school children (4th graders aged 9-10 years in Nouméa, the capital city, and its 
suburbs) from April to August 2013 in schools during the yearly screening 
programme (Part 2).  
 
2.3.3. Participants 
Participants for Part 1 were recruited through previous yearly echo-screening 
campaigns conducted in New Caledonia since 2008 (then aged 9-10 years). 
Participants in part 1 included children with subclinical RHD and children with 
previously normal echocardiograms.63 Part 1 was undertaken at the ASS-NC. 
Schoolchildren taking part in the yearly screening programme in Nouméa and its 
suburbs in April-July 2013 were offered to participate in Part 2 of this study. 
 
2.3.4. Echocardiography protocols 
The reference approach is identical to the methodology described in Section 2.2.4. 
Briefly, cardiologists performed standard echocardiograms with a portable machine 
(Vivid I, GE®, Milwaukee, WI) following a predefined acquisition protocol. An 
experienced reader (the PhD candidate) reviewed the studies using WHF criteria, 
blinded to clinical data. 
 
The FCU approach was defined by the evaluation of on-site screening using a pocket 
echocardiography device, carried out by two nurses trained specifically for the 
purpose of the study. The pocket-echo machine used was the V-scan (General 
Electrics, GE®, Medical Systems, version1.2, Milwaukee, WI), with a 1.7-MHz to 
3.4-MHz transducer. The V-scan offers regular greyscale imaging and colour blood 
flow mode with a 75° imaging sector. Grey-scale and Colour Doppler parasternal 
long axis and parasternal short axis, apical four chambers, two chamber and three 
chamber views were acquired, saved on the device’s micro-SD card and transferred to 
a computer. Distance measurements were performed during the examination using a 
caliper.  
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Each participant underwent three echocardiograms the same day in a randomly 
allocated order, blinded to the child’s diagnosis and to the other sonographer’s 
findings: two independent examinations by nurses using FCU and one examination by 
a cardiologist on-site. Each participant was assigned a unique research identification 
number, which could be used to link the imaging studies to the research participant.  
 
2.3.5. Training sessions 
Two nurses with no previous experience in echocardiography underwent focused 
training for the recognition of left-sided valve abnormalities. The aim and stepwise 
methodology used for training the nurses are based on the training schemes supported 
by the WHF and that were under way at the time of the study.65 The objectives of the 
training scheme were to gradually: (i) introduce the basic knowledge in 
cardiovascular physiology and cardiac anatomy; (ii) recognize the long and short axis 
parasternal, and all 3 apical transthoracic views, the four chambers and the four 
cardiac valves; (iii) acquire the views in grey scale and use colour Doppler; (iv) 
recognize morphological changes of the mitral valve (thickening of the anterior leaflet 
and of the chordae, restriction of the posterior and anterior leaflet, prolapse of the tip 
of the mitral leaflet); (v) detect the presence of mitral and/or aortic regurgitation; (vi) 
measure the maximum mitral regurgitation length using the caliper function on the 
device. 
Training included theoretical lectures for 3 days, followed by 30 hours 2 to 1 hands-
on sessions (with normal volunteers followed by sessions with patients at the 
echocardiography laboratory at CHT) in February 2013. Further tailored tutorship was 
undertaken after a preliminary assessment of the nurses’ capacities, after completion 
of part 1. Nurses then reviewed a set of 50 of their scans with an experienced reader 
(PhD candidate) and undertook 12-hours practical sessions (one to one sessions) 
addressing the pitfalls of each nurse (acquisition, interpretation). Nurses were not 
asked to detect lesions of other aetiologies, namely CHD.  
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Figure 2.4. Methods of study n°2.  
 
 
2.3.6. Outcomes measures 
Part 1. The sensitivity and specificity of various echocardiography criteria were 
assessed individually and in combination. Equal importance was given to sensitivity 
and to specificity in order to test a method that would be applicable in remote and 
deprived regions with no need for further diagnostic testing. 
The different echocardiographic criteria tested in part 1 were: (i) any mitral 
regurgitation (MR); (ii) MR jet length ≥1.5 cm; (iii) MR jet length ≥2.0 cm; (iv) 
morphological changes of the mitral valve defined as any irregular/focal thickening of 
the mitral leaflet, chordal thickening, restricted leaflet motion, excessive leaflet 
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motion or flail; (v) any aortic regurgitation (AR); (vi) MR jet length ≥2.0 cm or any 
AR.  
 
Part 2. The ability to detect RHD (borderline and/or definite RHD) was evaluated by 
comparing FCU (on-site diagnosis by nurses performing FCU by pocket-
echocardiography) to the reference approach. 
 
2.3.7. Bias 
The underlying prevalence of RHD may impact on the case detection rates, with 
possibly more false positives in low-prevalence areas where mitral regurgitation is 
likely to be physiological. Also the severity of heart valve disease may influence the 
ability to accurately detect RHD by FCU.  
 
2.3.8. Statistical methods 
Participant characteristics were described as median [IQR], mean [SD] or proportions, 
as appropriate. Categorical variables were compared using chi-square test. Sensitivity 
and specificity were calculated for the detection of any RHD (including borderline 
and definite RHD as per WHF criteria), with 95% CI. Confidence intervals for 
sensitivity and specificity were computed using the log-odds scale. Additional 
sensitivity analysis was performed for definite RHD cases. A predefined analysis was 
performed for part 1 of the study, including: (i) sample size calculations based on the 
hypothesis that the FCU approach would yield a sensitivity of 80% with 95%CI of 
70-90% if 61 definite RHD and 61 controls were included in the study; (ii) the 
sensitivity and specificity to detect RHD for both nurses, with predefined cut-off 
values of 70%, in order to prospectively implement a simplified algorithm in part 2. 
To evaluate agreement between investigators, we used kappa coefficient with 95% CI 
or percentage of agreement, as appropriate. Perceived differences in image quality 
(qualified as poor, moderate and good) by the two non-expert users according to the 
readings of the PhD candidate were compared between the two users using Bowker’s 
test of symmetry. All data were analysed with the use of Statistical Analysis System 
software (version 9.3).  
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2.3.9. Ethics 
Participants were enrolled after parental written consent. Ethical clearance was 
granted from the Committee for the Protection of Persons of Overseas Territories and 
from the French Institute of Medical Research and Health. 
 
 
2.4. Study 3: Symptomatic Rheumatic Heart Disease: estimated prevalence, 
incidence, characteristics and outcomes in New Caledonia 
 
2.4.1. Aims 
The main objective was to describe the characteristics of patients admitted to hospital 
for or with RHD, to estimate prevalence and incidence of RHD, and to assess 
outcomes in those who presented with newly diagnosed (or incident) RHD. The 
secondary objective was to identify factors associated with poor outcomes defined by 
a composite cardiovascular endpoint. 
 
2.4.2. Study design 
Retrospective hospital-based cohort with systematic review of hospital charts and 
cross-sectional follow-up to assess outcomes. 
 
2.4.3. Participants 
Hospital records of all individuals with a primary or secondary ICD 10 separation 
diagnosis of ARF or RHD from January 1st 2005 to December 31st 2012 were 
examined. Patients admitted with RHD in 2013 were prospectively enrolled. Patients 
who fulfilled WHF criteria for definite RHD were included in the study.53 A subset of 
patients with newly diagnosed RHD between 2005 and 2013 with quantification of 
heart valve disease was considered for the analysis of outcomes.66  
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2.4.5. Data collection and outcomes 
Data collected at the time of diagnosis 
For each participant, the following data were retrospectively collected: demographics 
(age, sex), ethnicity, month and year of diagnosis, family history of RHD, ARF at 
presentation, valve disease on first echocardiogram and its severity,67 NYHA class, 
LVEF on echocardiogram, pulmonary hypertension on echocardiogram (defined as 
pulmonary artery systolic pressure > 35 mmHg), presence of supraventricular 
arrhythmias (defined as paroxysmal or permanent atrial fibrillation, atrial flutter or 
atrial tachycardia). Mild heart valve disease included mild single left-sided valve 
disease and mild multiple heart valve disease (e.g., mild mitral regurgitation and mild 
aortic regurgitation). Heart valve disease was considered moderate if one of the left 
sided valves presented with moderate mitral regurgitation, mitral stenosis or aortic 
regurgitation. One single severe left-sided regurgitative/stenotic valve lesion was 
considered severe heart valve disease.67 
 
Follow-up 
Patients were invited to attend a specialist clinic from March 2013 to December 2013. 
If patients could not attend, a questionnaire was filled over the telephone either with 
the patient or the general practitioner, and the latest medical reports were collected. 
Data on treatment included use of secondary prophylaxis (benzathine penicillin G 
injections or oral treatment), at any time from diagnosis and at the time of interview 
(i.e., on-going secondary prophylaxis). The National Register of Secondary 
Prophylaxis held by the ASS-NC was consulted when data was missing on the 
hospital chart. The population being captive, all major events (see below) such as 
heart failure, stroke or embolism would lead to admission to CHT. Vital status and 
cause of death were checked in the national mortality register (DASS) in March 2014 
for patients lost to follow-up between March and December 2013. Use of cardiac 
interventions through the EVASAN office (in charge of overseas referrals) was also 
checked in March 2014 for patients lost to follow-up.  
 
Outcomes and factors associated with events 
Major cardiovascular events (MACE), based on information available in the hospital 
chart or in outpatients’ clinic letters, included: heart failure (defined by NYHA class 
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III or IV), peripheral embolism, stroke, heart valve intervention, and cardiovascular 
death. Heart valve interventions included percutaneous mitral valvuloplasty and open-
heart valve surgery. Additional adverse events were collected: severe haemorrhage 
(defined as leading to death, intra-cranial bleeding, bleeding associated with 
haemoglobin drop of ≥2g/dL or need for transfusion of at least 2 red-cell packs), 
infective endocarditis (defined as possible or definite infective endocarditis according 
to modified Duke criteria)68, heart valve thrombosis (in patients with a mechanical 
valve), cardiogenic shock, and pregnancy-related complications (defined as maternal 
or foetal complications, including heart failure, need for surgery, termination of 
pregnancy, pre-term birth, and low-birth weight).  
The analysis focused on patients with newly diagnosed RHD who presented with no 
MACE at the time of diagnosis. 
A team of two research nurses collected all the data. A third party (the PhD candidate) 
arbitrated in case of disagreement. 
 
2.4.6. Bias 
Given the retrospective nature of this work there are a certain number unavoidable 
bias. Only patients admitted to a tertiary centre were included, with potential referral 
bias of most severe cases during a 9-year period. This is also true for the prevalence 
estimates; patients with RHD not seeking assistance to the hospital between 2005 and 
2013 could not be included. The reason for reporting this prevalence estimate is to 
allow comparison of hospital and population-based data in the New Caledonian 
population. 
Missing data have contributed to diminishing the sample size. Restricting the study 
population to patients with strict echocardiographic criteria reduced further our 
sample size and may introduce a bias. The analysis focused on patients admitted with 
uncomplicated RHD at the time of diagnosis, which underestimates the burden of the 
disease, but allows the identification of factors associated with the advent of adverse 
outcomes. Missing data precluded the inclusion of secondary prophylaxis in the main 
Cox proportional hazard analysis, with however the possibility to perform sensitivity 
analysis. Secondary prophylaxis could not be treated as a time-dependent variable 
given the difficulties in estimating adherence to treatment in spite of multiple sources 
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of data collection. Diagnosis of ARF was at the discretion of the physician, and did 
not necessarily fulfil modified Jones’69 or Australasian criteria.64 
 
2.4.7. Statistical methods 
 
The incidence (person-years) of newly diagnosed RHD and of ARF is presented with 
Poisson 95% CI. The prevalence of RHD was also computed for 2013. The New 
Caledonian Bureau of Statistics population estimates published in 2014 were used for 
population denominators for the total, Melanesian and class-age populations. 
The results are reported as median and interquartile range (IQR) or as numbers and 
percentages. Categorical variables were compared using chi-square test or Fisher’s 
exact test, and continuous variables using Student t-test. Only patients with no MACE 
at hospital admission were further eligible for the analysis on incident MACE. The 
incidence of cardiovascular events was calculated per 1,000 person-years. Factors 
associated with MACE were analysed using a Cox proportional hazard model. Time 
to event was calculated as time from diagnosis to first event or last follow-up. Hazard 
Ratios (HR) for the Cox model were calculated accordingly with their 95% 
confidence intervals (CI). Sensitivity analysis was performed in regards to secondary 
prophylaxis. Significance was defined as P-values less than 0.05. All data were 
verified and analysed with the use of Statistical Analysis System software (version 
9.3). 
 
2.4.8. Ethics 
Patients were asked to give oral consent to be enrolled in the study at time of follow-
up interview. Ethical clearance was provided accordingly by the IRB Ethical Review 
Committee of the Institut National de la Santé et de la Recherche Médicale (French 
Institute of Health and Medical Research), Paris, France who waived written consent. 
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3. Results 
 
3.1. Study 1.  Part 1. Lessons from the first nationwide echocardiography-based 
screening programme for Rheumatic Heart Disease 
A public health campaign targeting schoolchildren in New Caledonia 
 
3.1.1. Abstract  
Background. The World Health Organization recommends active surveillance of 
Rheumatic Heart Disease (RHD) in endemic regions. Echocardiography has emerged 
as an early diagnostic tool. This is the first nationwide echocardiographic screening 
campaign for RHD in schoolchildren.  
 
Methods. A screening programme based on systematic use of ultrasounds to detect 
RHD was undertaken (2008-2011) by the government of New Caledonia. Children 
with suspected abnormalities were referred to cardiology clinics where final diagnosis 
was made. Were analyzed factors associated with the presence of RHD, and methods 
of the survey were assessed. 
 
Results. Among the 18,621 children targeted by the programme (82.1% of the 
population born 1998-2001), 17,287 (92.8%) were finally screened, 1,619 (9.4%) 
were referred for a second opinion on non-portable equipment, and 418/1,619 
(25.8%) did not attend the clinic. Out of the 17,287 schoolchildren screened, 157 were 
actually diagnosed with RHD (overall prevalence of 9.5 per 1,000 [95% CI 8.1-11.1]), 
with higher prevalence among older children (aged ≥11 years) (p=0.04), Oceanic 
populations (p<0.0001), and remote locations (p<0.0001). The majority of children 
(353/418, 84.4% cases) with lesions at school who were lost to diagnosis within the 
referral system were suspected of RHD and were at high risk according to their 
demographic characteristics. 
 
Conclusions. A nationwide program of echocardiography-based screening for RHD 
provides valuable data for future policy planning. Although feasible, the methods 
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carry a number of limitations, including a two-step diagnostic procedure leaving large 
numbers undiagnosed. 
 
3.1.2. Introduction  
Rheumatic Heart Disease still yields high prevalence rates in the Pacific and in 
Australia among indigenous populations.22, 28, 70 In contrast, the condition has been 
nearly eradicated in other French overseas islands over two decades ago by means of 
classic comprehensive prevention programmes.71  
One of the recommended strategies by the World Health Organization includes active 
surveillance in order to detect the disease in its early course and start secondary 
prophylaxis by penicillin, the only treatment proven to prevent progression of the 
disease.35 The use of ultrasounds has been shown to be of particular interest to 
increase case-detection, considering also silent RHD lesions.19, 47, 48, 72 The advent of 
new technological capacities that could reduce the burden of disease has increased the 
interest of the international community for this neglected condition.73 However, 
before ultrasounds may become an attractive tool for active surveillance, several 
issues need to be addressed.55, 74 To date, all studies have focused on samples driven 
from the population, as part of specific research programmes,19, 47-50, 72 and finally 
none has addressed the epidemiological perspective by targeting an entire population. 
A first nationwide active surveillance program based on the echocardiographic 
diagnosis of RHD targeting schoolchildren had been launched in New Caledonia, 
conducted under the auspices of the ASS-NC in the attempt to control the burden of 
the disease 
This is a unique opportunity to assess the methods and results of the first survey of the 
kind.  The advantages and limitations of this strategy are explored here. 
 
3.1.3. Methods  
These have been described in detail in Section 2.1. In summary, the ASS-NC 
undertook a nationwide screening yearly campaign targeting 4th graders in all primary 
schools. The diagnosis was based on echocardiographic features of RHD according to 
predefined criteria agreed amongst the local Cardiology community.  
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3.1.4. Results  
 
Completeness of the active surveillance program  
Among the 18,621 children listed in the active surveillance program, the majority 
(17,697; 95%) were born between 1998 and 2002 and represented approximately 
82.1% of the overall New Caledonian population born 1998-2002.  
Out of the 18,621 targeted by programme, 858 (4.6%) were absent the day of 
screening, and 376 (2.0%) provided no parental consent. Among the 17,287 children 
finally screened, 1,619 (9.4%) were referred for a second opinion on non-portable 
equipment, and 418/1,619 (25.8%) did not attend the clinic.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Completeness of the screening programme. 
85 known RHD/ARF 
858 did not attend 
376 no parental consent 
2 children refused 
13 missing data 
 
17,287 children screened 
1,619 referred for second echo 
18,621 4th graders 
15,668 normal echo 
418 did not attend 
146 MR unknown origin 
95 CHD 
41 degenerative MV 
4 cardiomyopathy 
3 missing data 
 
755 normal 2nd scan 
16,423 non-RHD 157 confirmed RHD cases 
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RHD Prevalence and factors associated with features of RHD 
One hundred and fifty-seven children were finally diagnosed with asymptomatic 
RHD following this two-step echocardiographic approach (i.e., presented no history 
of ARF or previously known RHD) giving an overall prevalence of 9.5 per 1,000 
[95% CI 8.1-11.1]. Stratified according to the year of screening, the prevalence of 
RHD was significantly higher in: older children (aged ≥11 years) (p=0.04), Oceanic 
populations (p<0.0001) and remote locations (Northern and Loyalty Islands 
Provinces) (p<0.0001).  
 
 
RHD 
N=157 
Non-RHD 
N=16,423 
Prevalence per 
1,000 
Univariate 
p 
Multivariate 
p 
Year of screening, n (%) 
2008 
2009 
2010 
2011 
 
39 (24.84) 
33 (21.02) 
44 (28.03) 
41 (26.11) 
3959 (24.11 
4238 (25.81) 
4192 (25.53) 
4034 (24.56) 
 
9.8 [ 6.9- 13.3] 
7.7 [ 5.3- 10.8] 
10.4 [ 7.6- 13.9] 
10.1 [ 7.2- 13.6] 
 
 
 
Age, mean (SD) 9.86 (0.76) 9.76 (0.70) 
 
 
0.07 
 
 
Age class*   
 
 
0.04 
 
0.04 
≤ 9 years 
10 years 
≥11 years 
 
40 (25.64) 
93 (59.62) 
23 (14.74) 
 
5703 (34.93) 
8771 (53.72) 
1854 (11.35) 
 
7 [ 5- 9.5] 
10.5 [ 8.5- 12.8] 
12.3 [ 7.8- 18.3] 
 
 
 
Sex, n (%)    0.18 0.12 
  Female 86 (54.78) 8113 (49.40) 10.5 [ 8.4- 12.9]   
  Male 71 (45.22) 8310 (50.60) 8.5 [ 6.6- 10.7]   
Province, n (%) 
Loyalty Islands 
Northern Province 
Southern Province 
23 (14.65) 
66 (42.04) 
68 (43.31) 
 
1678 (10.22) 
3105 (18.91) 
11640 (70.88) 
 
 
13.5 [ 8.6- 20.2] 
20.8 [ 16.1- 26.4] 
5.8 [ 4.5- 7.4] 
<0.0001 
 
 
<0.0001 
 
Location, n (%) 
Noumea 
Suburbs of Noumea 
Outside greater Noumea 
 
32 (20.38) 
27 (17.20) 
98 (62.42) 
 
6451 (39.28) 
4025 (24.51) 
5947 (36.21) 
 
 
4.9 [ 3.4- 7] 
6.7 [ 4.4- 9.7] 
16.2 [ 13.2- 19.7] 
<0.0001 
 
 
Ethnicity†, n (%) 
Caucasian or Asian 
Melanesian 
Polynesian 
 
 
11 (7.01) 
137 (87.26) 
9 (5.73) 
 
 
5609 (34.17) 
9243 (56.31) 
1553 (9.46) 
 
 
2 [ 1- 3.5] 
14.6 [ 12.3- 17.2] 
5.8 [ 2.6- 10.9] 
<0.0001 
 
 
<0.0001 
Table 3.1. Factors associated with asymptomatic RHD.  
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 The 418 children who were suspected of cardiac lesions at school and who did not 
attend the 2nd echocardiography were significantly older (p=0.02), more often male 
(p=0.008), from the Northern Province (p<0.001), and predominantly Melanesian 
(p<0.0001) when compared to the 1,201 children seen at the cardiology clinic. The 
rate of attendance to the clinic improved over time (p<0.001). Among the large 
numbers of children (25.8%) with lesions at school who were lost to diagnosis within 
the referral system, the majority (353/418, 84.4% cases) were suspected of RHD and 
were at high risk according to their demographic characteristics. 
 
3.1.5. Discussion  
 
I report here the results of a unique program that has aimed at mass echo-screening 
for RHD; the majority (82.1%) of the children in a specific age group being captured 
by the school-based survey between 2008 and 2011. The analysis of a nationwide 
program provides valuable data in the planning of future healthcare policies regarding 
RHD. The survey presents a number of advantages and limitations. The population at 
risk of RHD is defined by ethnicity, place of residence, and age group. Although 
feasible, there are several limitations inherent to the methods used. Pitfalls in the 
completeness of the active surveillance campaigns are mainly the consequence of a 
two-step diagnostic transversal approach since a significant proportion of children 
(25%) with suspected lesions at school are finally lost to follow-up with no definite 
diagnosis or treatment.  
 
The prevalence of RHD varied greatly across the different ethnic groups. Oceanic 
(i.e., Melanesian and Polynesian), especially Melanesian, children were at higher risk 
of RHD when compared to non-Oceanic children. Also, the prevalence was 
independently higher in the Northern and Loyalty Islands Provinces, two remote 
regions with less access to specialized care. Targeting population at risk may avoid 
consuming a vast amount of resources that could be otherwise used to strengthen the 
RHD control programme. 
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The programme missed children at risk for RHD: absentees (no systematic second 
visits were scheduled), those out of school, but, most importantly, those who did not 
attend the cardiology clinic for a second confirmatory echocardiogram. A two-step 
approach to diagnose RHD has been used in many studies, inviting children suspected 
at school to attend a cardiology clinic using non-portable sophisticated equipment.19, 
48, 50 Although ideal from an imaging perspective, a fourth of the children with 
suspected abnormalities did not attend the free of charge cardiology clinic. These 
children are at high risk of RHD based on their age, ethnicity and geographic location. 
On the other hand, the majority of children referred for a second scan did not have 
RHD. These facts highlight the two main limitations of a two-step approach: children 
at higher risk of RHD may not attend the confirmation scan and miss the opportunity 
of early medical treatment; whilst the cardiology clinics’ capacity is overwhelmed by 
a majority of healthy children. Studies exploring more simple and affordable ways to 
accurately diagnose RHD on site are most needed to render echocardiographic 
screening affordable and feasible in poorly resourced settings.75, 76  
 
These results open new perspectives in public health RHD research. Indeed, several 
issues need to be explored before the most appropriate methods for active surveillance 
are identified. Surveys tailored to the local epidemiology that prioritize populations at 
risk, serial screening throughout childhood, simpler ways of conducting echo-
screening (e.g., one step approach with on site diagnosis), and cost-effectiveness need 
to be addressed before transposing such programs to resource-deprived settings. 
 
3.1.6. Conclusions 
The first nationwide program of echocardiography-based screening for RHD in 
schoolchildren provides valuable data for future planning of healthcare policies. 
Although feasible, such methodology carries a number of limitations that need to be 
highlighted: a complex diagnostic approach leaves up to one fourth of suspected cases 
undiagnosed. These results suggest that screening restricted to high-risk populations 
(indigenous populations living in remote areas and overcrowded living conditions) 
should also be explored. Simplified approaches, and cost-effectiveness need to be 
addressed before transposing such programs to resource-deprived settings. 
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3.2. Study 1. Part 2.  Outcomes of asymptomatic echocardiography-screened 
rheumatic heart disease 
 
3.2.1. Abstract 
Objective – To assess the outcomes of Rheumatic Heart Disease (RHD) diagnosed by 
means of echocardiography-based screening. 
 
Methods – A cohort of children with and with no RHD was driven from a systematic 
echocardiography-based nationwide surveillance among 4th grade (age 9-10 years) 
schoolchildren in New Caledonia (2008–2011).  
 
Results - Out of 17,633 children screened, 157 were detected with findings of RHD. 
Among them, 114 consented children (76.5%) were enrolled (RHD-group), and were 
compared to 227 randomly selected healthy classmates (non-RHD group). After a 
median follow-up period of 2.58 years [1.31-3.63], incidence of ARF was similar in 
RHD and non-RHD groups (p=0.23): 10.28/1000/year and 3.31/1000/year, 
respectively. By echocardiography, 90 children in the RHD group (78.9%) still 
presented with RHD at follow-up, compared to 31 (13.7%) in the non-RHD group 
(p<0.0001). Only 12 children (10.5%) experienced progression of RHD over time, 
mild single valve disease lesions remaining unchanged in the majority of cases (61 
out of 73, 83.6%). Overcrowded living conditions were independently associated with 
persistent RHD on echocardiography (OR 8.27 95% CI (1.67-41.08), p<0.01). 
Benzathine penicillin G was given in 88.6% of children in the RHD-group.  
 
Conclusions – Children screened positive for RHD by echocardiography have mostly 
mild but irreversible heart valve disease under secondary prophylaxis. These findings 
also suggest that a single screening point in childhood may prove insufficient in high-
risk populations. 
 
3.2.2. Introduction 
Echocardiography-based screening may present an attractive method for RHD 
control, ultrasounds being more sensitive to detect very mild valve lesions.19 
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However, the natural history of echocardiography-detected RHD has never been 
established and the need for secondary prophylaxis still remains debated.77, 78 There 
are therefore several unanswered questions in the field, as the outcomes of children 
screened for RHD, the need for secondary prophylaxis, and the target age-range. I 
assessed here the outcomes through a cohort study of children with and without RHD 
who took part in the first large RHD echocardiography-based surveillance program.  
 
3.2.3. Methods 
These have been described in detail in Section 2.2. Briefly, I conducted the follow-up 
of a cohort of children with findings of RHD and matched controls. The aim of the 
study was to assess the outcomes of children detected by echocardiography as having 
RHD (RHD group), compared to those without RHD (non-RHD group). In addition, 
factors associated with persistence or progression of disease were identified. 
 
Participants 
Among the 17,633 children screened, 157 were diagnosed with RHD (i.e., presented 
no history of ARF or previously known RHD). One hundred fourteen out of 157 
(72.6%) consented to be finally enrolled in the specific follow-up program, including 
secondary prophylaxis by oral or injectable penicillin. Among the children with no 
RHD on echocardiogram between 2008 and 2011, 227 classmates were randomly 
selected matched according to ethnicity (and classroom). 
 
 
3.2.4. Results 
 
Characteristics according to the initial diagnosis 
One hundred and fourteen children with RHD diagnosed by echocardiography and 
227 previously healthy children participated in the study. The mean age (SD) at the 
time of screening was 9.9±0.7 in the RHD group, and 10.0±0.7 in the normal baseline 
echocardiography group (non-RHD group), with a sex ratio (M/F) of 0.9 in the RHD 
group and of 1.0 in the non-RHD group.  
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Figure 3.2. Flow chart of the cohort study on outcomes in asymptomatic 
echocardiography-screened RHD.*Other diagnosis after serial echocardiography 
(CHD). 
 
Among the 114 children with a positive screening for RHD, the baseline 
echocardiogram showed mitral regurgitation in 107 cases (93.9%), aortic 
regurgitation in 34 cases (29.8%), and mitral stenosis in 6 cases (5.2%). Multiple left-
sided valve involvement was present in 30 (26.3%) cases. Available in 60 cases, 
median baseline left ventricular ejection fraction was 65% IQR (61-70.5). 
Physiological mitral regurgitation was present in 16 out of 227 (7.1%) children with 
normal findings on the echocardiogram at school.  
 
18,621 children in 4th grade 
85 known RHD/ARF 
858 did not attend 
376 no parental consent 
2 children refused 
13 missing data 
 
17,287 children screened 
157 RHD children 
1 declined 
3 excluded* 
39 lost to FU 
5 declined 
4 excluded* 
227 non-RHD children at FU 114 RHD children at FU 
16,423 non-RHD children 
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Table 3.2. Characteristics of children at baseline. *Age at the time of screening. †Includes 
Melanesians and Polynesians. ‡Defined as a University/College degree. §Defined as having 
a concrete floor but with traditional walls and/or roofs (wood and palm trees) 
 
Outcomes of children with RHD 
The incidence of ARF was of 10.28/1,000 person-years after a median follow-up 
period of 2.58 years [1.31-3.63]. One child (0.9%) suffered from heart failure during 
Characteristics RHD 
N=114 
Non-RHD 
N=227 
Number of years to FU, median (IQR) 2.2 (1.5-3.6) 2.6 (1.3-3.6) 
Year of screening, n (%) 
  2008 
  2009 
  2010 
  2011 
 
29 (25.4) 
24 (21.0) 
32 (28.1) 
29 (25.4) 
 
54 (23.8) 
54 (23.8) 
53 (23.3) 
66 (29.1) 
Age*, mean (SD) 9.9 (0.7) 10.0 (0.7) 
Male, n (%) 54 (47.4) 115 (50.7) 
Province, n (%) 
  Loyalty Islands 
  Northern Province 
  Southern Province 
 
16 (14.0) 
46 (40.3) 
52 (45.6) 
 
31 (13.7) 
115 (50.7) 
81 (35.7) 
  Ethnicity, n (%) 
  Oceanic† 
  Caucasian 
  Other 
 
97 (85.1) 
4 (3.5) 
13 (11.4) 
 
185 (81.5) 
4 (1.8) 
38 (16.7) 
Number of siblings by mother, n (%) 
  ≤ 2 
  3-5 
  ≥ 6 
 
26 (22.8) 
66 (57.9) 
22 (19.3) 
 
48 (21.2) 
140 (61.9) 
38 (16.8) 
Maternal employment, n (%) 
  No formal occupation  
  Receives salary 
  Unknown 
 
55 (48.2) 
58 (50.9) 
1 (0.9) 
 
109 (48.0) 
107 (47.1) 
11 (4.8) 
Maternal education, n (%) 
  Primary school 
  Secondary school 
  High education‡ 
  Unknown 
 
51 (44.7) 
48 (42.1) 
7 (6.1) 
8 (7.0) 
 
119 (52.4) 
88 (38.8) 
10 (4.4) 
10 (4.4) 
Housing, n (%) 
  Concrete 
  Partly concrete§ 
  Non-concrete 
  Unknown 
 
71 (62.3) 
32 (28.1) 
10 (8.9) 
1 (0.9) 
 
127 (55.9) 
76 (33.5) 
22 (9.7) 
2 (0.9) 
Lived ≥1 year out of the household, n (%) 35 (30.7) 63 (27.7) 
Usual mode of transport: private car, n (%) 78 (68.4) 137 (60.3) 
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the follow-up period. No heart valve interventions were carried out during the study 
period.  
Twenty-four children (21.0%) in the RHD group presented with an audible 
pathological murmur at follow-up. Eleven out of these 24 children (45.8%) had valve 
disease grade ≥2/4 on the follow-up scan.  
One hundred and one children out of 114 cases (88.6%) received benzathine penicillin 
G. The periodicity of penicillin injections over the follow-up period is described in 
Figure 3.3. Six (5.3%) were offered oral secondary prophylaxis and 7 (6.3%) received 
no antibiotics. 
 
 
Figure 3.3. Periodicity of benzathine penicillin injections in children with RHD. 
 
Among the 114 initial cases, 41 (36.0%) presented with a definite diagnosis of RHD 
at follow-up; 49 (43.0%) had features consistent with borderline RHD; and 24 
(21.1%) had normal findings according to the WHF criteria.53 
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Figure 3.4. Echocardiographic diagnosis at follow-up. FU, follow-up. 
 
Among the 24 out of 114 RHD cases who did not fulfil the WHF criteria for RHD on 
the FU scan, 19 presented with mild mitral regurgitation (i.e., grade 1/4), 2 with a 
combination of mild mitral regurgitation and mild aortic regurgitation, 1 with mild 
aortic regurgitation, and 2 children had no aortic or mitral regurgitation. Thus, among 
the 114 children with RHD, 112 (98.2%) were deemed to have significant left-sided 
regurgitation on the follow-up echocardiogram regardless WHF criteria. 
Neither hospital admission nor deaths were reported among the children lost to 
follow-up between January 1st 2008 and August 1st 2013. 
 
Factors associated with the persistence of RHD among the group of children with 
RHD were identified. Univariate analysis of the persistence of RHD (either definite or 
borderline RHD) is presented in Table 3.3. On multivariate analysis, stratified 
according the year of screening, the number of people per bedroom remained the only 
significant factor associated with persistence of RHD: number of people per bedroom 
< 3 vs. ≥ 3, OR 8.27 95% CI (1.67-41.08), p<0.01. The association remained 
significant when children with borderline RHD were excluded from the analysis: 
number of people per bedroom < 3 vs. ≥ 3, OR 7.70 95% CI (1.28-46.45), p=0.03. 
There was no significant association between persistence of RHD and compliance to 
secondary prophylaxis (p=0.78). 
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 Persistent RHD 
N=90 
Normal echo 
N=24 
Univariate 
P – value 
Multivariate OR 
(95% CI) 
Multivariate 
P - value 
Year of screening, n (%) 
2008 
2009 
2010 
2011 
 
24 (26.7) 
14 (15.6) 
28 (31.1) 
24 (26.7) 
 
5 (20.8) 
10 (41.7) 
4 (16.7) 
5 (20.8) 
   
Age*, mean (SD) 10.0 (0.7) 9.7 (0.9) 0.2   
Male, n (%) 45 (50.0) 9 (37.5) 0.3   
Ethnicity, n (%) 
Oceaniac† vs. European or 
Asian 
 
76 (84.4) 
 
21 (87.5) 
0.9   
Number of siblings by 
mother, n (%) 
  
 
0.2   
≤ 2 
3-5 
≥ 6 
22 (24.4) 
49 (54.4) 
19 (21.1) 
4 (16.7) 
17 (70.8) 
3 (12.5) 
   
Maternal employment, n (%) 
No formal occupation  
Receives salary 
 
45 (50.6) 
44 (49.4) 
 
10 (41.7) 
14 (58.3) 
0.4   
Maternal education, n (%) 
Primary school 
Secondary school 
High education‡ 
 
38 (46.3) 
41 (50.0) 
3 (3.7) 
 
13 (54.2) 
7 (29.2 
4 (16.7) 
0.048 1.97(0.69-5.64) 0.20 
Housing, n (%) 
Concrete 
In part concrete§ 
Non-concrete 
 
56 (62.9) 
8 (9.0) 
25 (28.1) 
 
15 (62.5) 
2 (8.3) 
7 (29.2) 
0.9   
Lived ≥1 year out of the 
household, n (%) 
29 (32.2) 6 (25.0) 0.2   
Usual mode of transport: 
private car, n (%) 
63 (70.0) 15 (62.5) 0.4 
 
  
Number of people per 
bedroom, n (%) ≥3 
 
32 (35.6) 
 
2 (8.3) 
 
0.003 
 
 
8.27(1.67-41.08) 
 
<0.01 
Penicillin injections§§, n (%) 
≤ 4 weeks 
> 4 weeks 
 
38 (42.2) 
44 (91.1) 
 
12 (50.0) 
11 (45.8) 
0.78   
Table 3.3. Factors associated with the presistence of RHD. *Age at the time of 
screening. †Includes Melanesians and Polynesians. ‡Defined as a University/College degree. 
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§Defined as having a concrete floor but with traditional walls and/or roofs (wood and palm 
trees).  §§Applicable for 105 children (6 received oral treatment and missing data in 3). OR, 
Odds Ratio. CI, Confidence Interval. 
 
The severity of valve disease in the RHD group at baseline and at follow-up is 
depicted in Table 3.4. Overall, 102 out of 114 children (89.5%) had unchanged 
severity of valve disease, whilst 12 (10.5%) experienced progression of their valve 
disease and none improved significantly. Six children (5.2%) presented with new 
valve lesions. Mild single valve disease lesions remained unchanged in the majority 
of cases (61 out of 73 cases, 83.6%). There was no significant association between 
outcomes in terms of valve disease severity and the number of people per bedroom <3 
vs. ≥ 3 (Fischer exact test, p=1); or the periodicity of penicillin injections (6 weekly 
injections or less vs. no injections or every periodicity over 6 weeks, Fischer exact 
test, p=0.08). 
 	   At	  baseline	  
N=114	  
At	  follow-­‐up	  
N=114	  
Mitral	  regurgitation,	  n	  (%)	   107	  (93.9)	   111	  (97.4)	  Physiological	  MR	  Grade	  1	  Grade	  2	  Grade	  3	  Grade	  4	  
7	  (6.1)	  79	  (69.3)	  18	  (15.8)	  3	  (2.6)	  0	  
44	  (38.6)	  58	  (50.9)	  6	  (5.2)	  1	  (0.9)	  1	  (0.9)	  
Aortic	  regurgitation,	  n	  (%)	   34	  (29.8)	   38	  (33.3)	  Physiological	  AR	  Grade	  1	  Grade	  2	  Grade	  3	  Grade	  4	  
7	  (6.1)	  23	  (20.2)	  3	  (2.6)	  1	  (0.9)	  0	  
18	  (15.8)	  17	  (14.9)	  2	  (1.8)	  1	  (0.9)	  0	  
Mitral	  stenosis,	  n	  (%)	   6	  (5.2)	   7	  (6.1)	  Mild	  Moderate	  Severe	  
5	  (4.4)	  1	  (0.9)	  0	  
4	  (3.5)	  2	  (1.8)	  1	  (0.9)	  
Multiple	  valve	  disease	   30	  (26.3)	   	  37	  (32.7)	  
Table 3.4. Echocardiographic features of heart valve disease 
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Outcomes of children with no RHD at the time of screening  
There was no significant difference in terms of incidence of ARF between the RHD 
and the non-RHD groups. The incidence of ARF was of 10.28/1,000 person-years and 
3.31/1,000 person-years in RHD and non-RHD groups (p=0.23), respectively. Three 
children (1.3%) in the non-RHD group presented with a murmur at follow-up. There 
were no complications, nor hospital admissions or death, in the non-RHD group. 
Among the 227 children with normal baseline echocardiograms, 2 (0.9%) presented 
with a definite diagnosis of RHD, 29 (12.8%) had features of borderline RHD, and 
189 (83.3%) presented normal findings at follow-up.53 
After stratification for the year of screening, children with an initial diagnosis of RHD 
had an increased risk [RR 5.60 (3.98-7.87), (p<0.0001)] to have an abnormal 
echocardiogram at follow-up (either definite or borderline RHD), compared to 
children with a normal baseline echocardiogram. 
 
3.2.5. Discussion  
 
This is, to the best of my knowledge, the largest cohort of children diagnosed with 
RHD and with no RHD by means of school-based echocardiography screening to this 
date. The majority of valve lesions, albeit mild, persist under secondary prophylaxis. 
Overcrowded living conditions were associated with the persistence of the disease. 
Children at risk of RHD with normal baseline echocardiograms when aged 9-10 years 
yield considerable risk of developing ARF or RHD later in adolescence. 
Most children with RHD (78.1%) presented with persistent disease according to the 
currently recommended criteria under secondary prophylaxis.53 These findings are in 
good agreement with smaller series, where RHD persisted in approximately 67-75% 
of cases. 50, 57, 58 Of note, left-sided valve disease, often mild and unchanged in 
severity, remained present in the vast majority of RHD children in our study. The 
apparent discrepancies in our results as regards to presence of RHD versus valve 
disease quantification may be explained by the fact that the WHF criteria are stringent 
in terms of pathological regurgitation. A complete continuous Doppler envelope of 
mitral regurgitation jet is necessary to validate the WHF criteria.53 But mitral 
regurgitation is classically posteriorly directed in RHD and a complete envelope may 
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be difficult to obtain, especially when valve disease is mild, as was the case in this 
study.  
 The number of people per bedroom was associated with the persistence of 
RHD on echocardiogram. Promiscuity increases the risk to GAS exposure, thereby 
leading to recurrent or chronic ARF attacks.79 These findings highlight the importance 
of taking into account risk factors for ARF when facing mild valve lesions that may 
be of rheumatic origin. Living conditions may become part of the decision-making 
process regarding secondary prophylaxis, especially in the setting of borderline RHD 
lesions in asymptomatic children.80  
Only one child out of 157 presented with a serious complication (heart failure that 
resolved under medical therapy). There were no interventions or deaths in our cohort, 
suggesting the benign course of echo-screened RHD. These results should be taken 
with caution given the relatively short follow-up period (2 years) whilst it usually 
takes decades before presenting with advanced disease.16, 81 
Approximately half the RHD children received secondary prophylaxis as currently 
recommended by the latest regional guidelines.64 As in other countries, there is still 
place for improvement, especially in the setting of universal healthcare coverage as 
provided in New Caledonia.81-83 There was no significant association between the 
compliance to secondary prophylaxis and outcomes in terms of persistence of RHD or 
severity of valve disease, likely due to the study design. Data on the natural history of 
subclinical RHD are lacking and some experts in the field have questioned the need 
for secondary prophylaxis, especially in those diagnosed as borderline RHD.77 Since 
the landmark study that suggested echo-based screening as a possible option for 
disease-control,19 other groups have found that ultrasound-led diagnosis may be of 
interest, with higher sensitivity and specificity than auscultation.21 To the best of my 
knowledge, three prospective studies assessing the prognostic significance of 
subclinical RHD are currently on going.48, 84, 85 It may however take several years 
before data are available to establish guidelines in the field. In the meanwhile, these 
findings suggest that, based on the precautionary principle, secondary prophylaxis 
should be offered to these children given that their valve lesions remained stable 
under such (albeit imperfect) treatment. 
 
This study supports the need for another screening point later in childhood. Children 
with no RHD at age 9-10 years are at risk of developing ARF later in adolescence. 
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Age matters in terms of cumulative incidence of ARF and of the prevalence of 
RHD.21, 28, 52 Acute rheumatic fever incidence was similar in RHD and non-RHD 
groups. The annual incidence in this cohort is similar to figures reported in other 
regions.28, 86 In addition to high ARF incidence, a significant proportion of children 
with normal echocardiograms at school presented 2 years later with either definite 
RHD (0.9%) or borderline RHD (12.8%). Repeat screening may be an option to 
increase case-detection rates in those with mild disease that may benefit the most 
from secondary prophylaxis.  
 
Strengths and limitations 
In addition to what has been outlined in the Methods section 2.2.6, this study may 
have lacked power to assess clinical outcomes (i.e., ARF attacks). The study was 
neither designed nor powered to assess the impact of secondary prophylaxis on 
echocardiography-screened, often mild and subclinical, RHD. 
 
3.2.6. Conclusions 
 
Rheumatic heart disease diagnosed by echocardiography-based screening is often 
mild but nevertheless an irreversible condition in schoolchildren under secondary 
prophylaxis. Overcrowding appears to be the strongest predictor of the persistence of 
the disease. Serial assessment throughout childhood may be of interest. Further 
studies are warranted to assess the need for secondary prophylaxis in subclinical 
RHD. 
 
3.3. Study 2. Screening for Rheumatic Heart Disease: Evaluation of a Focused 
Cardiac Ultrasound Approach 
 
3.3.1. Abstract 
Objective – To compare FCU to a reference approach for RHD screening. 
 
Methods and Results – Prospective comparison of FCU to a reference approach for 
RHD screening in a school children population. FCU included (i) the use of a pocket-
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sized echocardiography machine, (ii) non-expert staff (two nurses with specific 
training), and (iii) a simplified set of echocardiographic criteria. The reference 
approach used standardized echocardiographic examination, reviewed by an expert 
cardiologist, according to 2012 WHF criteria. Among the six different 
echocardiographic criteria first tested in a preliminary phase (Part 1), mitral 
regurgitation jet length ≥2cm or any aortic regurgitation was considered best suited to 
be FCU criteria. Of the 1,217 subjects enrolled (mean 9.6±1 years, 49.6% male), 49 
(4%) were diagnosed with RHD by the reference approach (Part 2). The sensitivity of 
FCU for the detection of RHD was 83.7% (95% CI 73.3-94.0) for nurse A and 77.6% 
(95% CI 65.9-89.2) for nurse B. FCU yielded a specificity of 90.9% (95% CI 89.3-
92.6) and 92.0% (95% CI 90.4-93.5) according to users. Percentage of agreement 
among nurses was 91.4%.  When restricted to definite RHD only, the performance of 
the FCU approach was better. Focused cardiac ultrasound yielded a sensitivity of 
93.3% (95% CI 64.7-99.1) and 86.7% (95% CI 59.5-96.7) according to nurses A and 
B, respectively; the percentage of agreement between nurses was then 91.8%. 
 
Conclusions – Focused cardiac ultrasound by non-experts using pocket-devices 
appears feasible and yields acceptable sensitivity and specificity for RHD detection 
when compared to the state-of-the-art approach, thereby opening new perspectives for 
mass screening for RHD in low-resource settings. 
 
 
3.3.2. Introduction  
 
The WHO had recommended active surveillance of RHD in the past. There are 
however no guidelines as how screening should be undertaken. The WHF has 
provided guidelines to optimize echocardiographic RHD diagnosis.53, 56 There are 
certain issues that may prevent implementation of active surveillance by 
echocardiography in regions where RHD prevalence is highest.19, 48, 72 Concerns 
include the cost of comprehensive portable equipment, the complexity of 
echocardiographic criteria, and the need for highly trained health workers in countries 
where access to specialist care remains limited. All these factors represent significant 
barriers to mass screening in low-income countries.29 Echocardiography may however 
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emerge as the method of choice for active surveillance in highly endemic regions in 
this rapidly moving field.46  
 
Study n°2 prospectively assessed a new approach for RHD screening based on FCU 
combining the use of a pocket-size echo system, performed by nurses after a 
standardized training program, and using a simplified diagnostic algorithm. 
 
3.3.3. Methods  
 
Methods have been detailed in Section 2.3. Briefly, the study comprises two parts. We 
first tested the most appropriate simplified set of echocardiographic criteria for RHD 
to be used for FCU among 189 selected children with and without RHD in March 
2013 (Part 1 of the study). These children had previously participated in the yearly 
echo-screening campaigns conducted in New Caledonia since 2008 (then aged 9-10 
years). We then prospectively evaluated the feasibility and performance of a FCU 
approach among a population of school children (4th graders aged 9-10 years in 
Nouméa, the capital city, and its suburbs) from April to August 2013 (Part 2).  
 
3.3.4. Results  
Evaluation of the optimal simplified set of echocardiographic criteria for FCU 
approach – Part 1 
One hundred and eighty-nine children were enrolled in this preliminary study. Mean 
age was 12.2 years (SD 2.0) and 84 (44.4%) were male. One hundred and six (56.1%) 
children had findings of RHD (63 definite and 43 borderline RHD), whereas 83 
(43.9%) had normal echocardiograms.  
The breakdown of echocardiographic findings according to WHF criteria is presented 
in Table 3.5. 
Sensitivity and specificity of the six criteria interpreted by the nurses, when compared 
to the reference approach, are reported on Table 3.6 and Figure 3.5. Overall, there was 
an important heterogeneity with sensitivity varying from 26.4 (95% CI 18.9-35.6) to 
97.2 (95% CI 91.7-99.1), specificity from 13.5 (95% CI 7.6-20.9) to 91.6 (95% CI 
64.3-83.4), with also a wide range for inter-observer agreement (kappa varying from 
0.09 to 0.57).  
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Reference echocardiographic findings RHD 
N=106 (%) 
No RHD 
N=83 (%) 
All, 
N=189 (%) 
Definite RHD 63 (59.4) 0 63 (33.3) 
Borderline RHD 43 (40.6) 0 43 (22.8) 
MR 101 (95.3) 51 (61.4) 152 (80.4) 
Physiological MR 21 (19.8) 46 (55.4) 67 (35.4) 
MR grade 1 73 (68.9) 5 (6.0) 78 (41.3) 
MR grade 2 1 (9.4) 0  1 (0.5) 
MR grade ≥3 6 (5.7) 0  6 (3.2) 
AR 36 (34.0) 10 (12.0) 46 (24.3) 
Physiological AR 13 (12.3) 9 (10.8) 22 (11.6) 
AR grade 1 17 (16.0) 1 (1.2) 18 (9.5) 
AR grade 2 5 (4.7) 0  5 (2.6) 
AR grade ≥3 1 (0.9) 0  1 (0.5) 
Mitral stenosis (mean gradient≥4mmHg) 6 (5.7) 0  6 (3.2) 
MR : 
 
Seen in 2 views 
Jet length≥2cm 
Vmax≥3m/s 
Pan-systolic 
 
 
98 (92.5) 
80 (75.5) 
86 (92.0) 
58 (54.7) 
 
 
39 (47.0) 
9 (10.8) 
15 (18.1) 
0  
 
 
137 (72.5) 
89 (47.1) 
101 (53.4) 
58 (30.7) 
AR : 
 
Seen in 2 views 
Jet length≥1cm 
Vmax≥3m/s 
Pan-diastolic 
 
 
32 (30.2) 
32 (30.2) 
25 (23.6) 
20 (18.9) 
 
 
9 (10.8) 
8 (9.6) 
5 (6.0) 
0  
 
 
41 (21.7) 
40 (21.2) 
30 (15.9) 
20 (10.6) 
Morphological changes of the MV 
 
AML thicknening≥3mm 
Restricted leaflet motion 
Chordal thickening 
Excessive leaflet motion  
Flail 
 
 
45 (42.5)  
93 (87.7) 
90 (84.9) 
1 (0.9) 
2 (1.9) 
 
 
0  
1 (1.2) 
0  
0  
0  
 
 
45 (23.8) 
94 (49.7) 
90 (47.6) 
1 (0.5) 
2 (1.1) 
Morphological changes of the AV: 
 
Coaptation defect 
Restricted leaflet motion 
Prolapse 
Irregular or focal thickening 
 
 
3 (2.8) 
2 (1.9) 
4 (3.8) 
12 (11.3) 
 
 
0  
0  
0  
2 (2.4) 
 
 
3 (1.6) 
2 (1.1) 
4 (2.1) 
14 (7.4) 
Table 3.5. Echocardiographic findings  - Part 1.  
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Table 3.6. Sensistivity and specificity of all critieria tested in Part 1. 
 
Among the six criteria tested, the combined criteria of MR jet length≥2.0cm or any 
aortic regurgitation (regardless the length) appeared to achieve the best combination 
of sensitivity and specificity. Compared to the reference approach, sensitivity of the 
combined criteria to detect any RHD was 76.4% (95% CI 67.4-83.5) and 70.7% 
(95%CI 61.4-78.6) for nurses A and B, respectively. The specificity to detect any 
RHD was of 73.5% (95%CI 63.0-70.7) and 69.9% (95%CI 59.2-69.1) according to 
nurses A and B, respectively.  
 
 
 
Figure 3.5. Sensitivity and specificity of all criteria tested in Part 1. 
 
Criteria tested Sensitivity 
nurse A 
Sensitivity 
nurse B 
Specificity 
nurse A 
Specificity 
nurse B 
kappa 
MR 87.7 (80-92.7) 97.2 (91.7-99.1) 55.4 (44.6-59.9)  13.5 (7.6-20.9) 0.27 (0.14-0.40) 
MR ≥ 1.5 cm 81.1 (72.5-87.5) 84 (75.8-89.8)  69.9 (59.2-69.1) 57.8 (47.0-61.6) 0.47 (0.35-0.60) 
MR ≥ 2.0 cm 67 (57.5-75.3) 83.1 (73.5-71.9) 66 (56.5-74.4) 74.7 (64.3-71.1) 0.51 (0.39-0.63) 
Morphological 
changes of the MV 
61.3 (51.7-70.1) 54.7 (45.2-63.9) 57.8 (47-61.6)  74.7 (64.3-71.1) 0.09 (-0.05-0.23) 
AR 33 (24.7-42.5) 26.4 (18.9-35.6)  89.2 (80.5-68.1) 91.6 (64.3-83.4) 0.57 (0.43-0.71) 
MR ≥ 2.0 cm or AR 76.4 (67.4-83.5) 70.7 (61.4-78.6) 73.5 (63.0-70.7)  69.9 (59.2-69.1) 0.48 (0.35-0.60) 
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The agreement between nurses was moderate for the detection of all RHD cases when 
using the combined criteria (kappa value of 0.48, 95% CI 0.35-0.60). 
 
 
Figure 3.6. Echocardiograms by FCU. Right panel: MR jet length<2cm. Left pannel: 
MR jet length≥2cm. 
 
Assessment of image quality and on-site diagnosis – Part 1 
Image quality of the FCU recordings was evaluated as good in 68 (36.8%) and 79 
(42.7%), fair in 109 (58.9%) and 104 (56.2%), and poor in 8 (4.3%) and 2 (1.1%) 
cases, for nurses A and B, respectively (missing data in 4 cases), without significant 
difference between the two nurses (P=0.07).  
When an experienced cardiologist reviewed FCU recorded by nurses in the field, the 
sensitivity and specificity of the diagnoses made by the nurses were not statistically 
significantly different from the corresponding values obtained from the experienced 
cardiologist. Mean scanning time per FCU scan was 5.9 min (1.7) for nurse A and 7.0 
min (1.9) for nurse B.  
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Figure 3.7. Inter-reader variability of FCU examinations (acquired by the nurses). 
Light blue: nurse’s on site interpretation, dark blue: cardiologist’s interpretation 
after review of the nurses’ recordings. A, stands for "nurse A"; B for "Nurse B". 
 
Focused cardiac ultrasound in the population – Part 2 
Among the 1,217 children included at school (mean age 9.6±0.5 years; 603 male, 
49.6%), 49 (4.0%) were diagnosed with findings of RHD according to the reference 
approach, including 15 definite and 34 borderline RHD cases. 
The sensitivity of FCU to detect any RHD cases was 83.7% (95% CI 70.7-91.6) for 
nurse A and 77.6% (95% CI 63.9-87.1) for nurse B. Focused cardiac ultrasound 
yielded a specificity of 90.9% (95% CI 89.1-92.4) and 92.0% (95% CI 90.3-93.4) 
according to nurses A and B, respectively. The percentage of agreement between 
nurses was 91.4%. 
When restricted to definite RHD, the performance of the FCU approach was better. 
Focused cardiac ultrasound yielded a sensitivity of 93.3% (95% CI 64.7-99.1) and 
86.7% (95% CI 59.5-96.7) according to nurses A and B, respectively. The percentage 
of agreement between nurses was 91.8%. All RHD valve lesions detected in schools 
were graded as mild with no case of mitral stenosis.   
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Figure 3.8. Flow chart of the school-based study - Part 2.  
 
Combined criteria  Nurse A Nurse B 
Sensitivity of Any RHD (definite and borderline), N=49 83.7 (70.7-91.6) 77.6 (63.9-87.1) 
Sensitivity of Definite RHD only, N=15 93.3 (64.7-99.1) 86.7 (59.5-96.7) 
Specificity N=1168 90.9 (89.1-92.4) 92.0 (90.3-93.4) 
Combined criteria  Kappa Concordance 
Any RHD (definite and borderline), N=1217 0.57 (0.50-0.65) 91.4% 
Definite RHD only, N=1183 0.53 (0.44-0.61) 91.8% 
Table 3.7. Performance of FCU approach in schoolchildren. 
 
1862	  potentially	  eligible	  
participants	  in	  Nouméa 
1217	  children	  included 
	  453	  did	  not	  provide	  consent	  
	  142	  did	  not	  attend	  
	  50	  missing	  data	  
 
49	  RHD	  cases	   1168	  non-­‐RHD	  children	  
3334	  4th	  graders	  in	  the	  
Southern	  Province	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3.3.5. Discussion  
 
This study is the first evaluation of a FCU approach for RHD screening by non-
experts with pocket devices using simple echocardiographic criteria. Such an 
approach may be potentially applicable in many poorly resourced settings. After 
establishing an optimal simplified diagnostic algorithm for non-experts, the approach 
was tested in the field. These findings suggest that this approach, although imperfect, 
yields acceptable sensitivity and specificity (~80%) to detect RHD within minutes 
with no further readings when compared to the state-of-the-art approach.53  
 
Overall, this study tested a combination of three factors: (i) the adequacy of the 
pocket- echo machine in detecting RHD; (ii) the proficiency of the nurses after brief 
training; and (iii) the performance of simplified criteria combining MR jet ≥2.0cm or 
any AR (regardless of jet length). This global strategy incorporates affordable 
equipment by non-experienced users with the aim to be translated into public health 
policies with widespread applicability. 
 
Image quality of the pocket-echocardiograms was good or fair in the majority (~90%) 
of cases by two operators, as in other settings including adults with larger body 
habitus.87, 88 Beaton and colleagues have recently shown that pocket-echo (V-scan, 
GE®) was highly sensitive and specific (>90%) to diagnose RHD in a set of 
previously screened schoolchildren when operated by an experienced cardiologist 
with off-line interpretation by another experienced cardiologist on a dedicated 
software.75 Their findings are of the outmost importance since they demonstrate the 
technical capabilities of pocket-echo for RHD screening. However, the extent to 
which their methods could be translated into public health policies, in the light of a 
scarcity of specialized health workers in many low-income countries, remains 
questionable.29 Not surprisingly, the performance of pocket-echo in this study was 
lower, even when an experienced reader interpreted the nurses’ echocardiograms, 
suggesting that operators’ skills in acquiring the images may impact on the 
performance of a FCU strategy.  
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The choice to test non-experienced users was deliberate since it would be the most 
likely scenario in low-income countries. Sensitivity and specificity of the FCU 
approach were higher in Part 2 than in Part 1. Proficiency may have improved 
following additional tailored training between the two parts of the study, which would 
suggest the impact of longer training schemes on the accuracy of a FCU approach by 
non-experts. Several studies have tested FCU by non-experts with variable results. 
This may be due to high expectancies of FCU and to different training schemes.89, 90 
Echocardiography requires skilled users in image acquisition and during 
interpretation. Galderesi and colleagues showed that trainees yield lower performance 
when compared to experienced cardiologists, in spite of 15 hours of lectures and 
approximately 150 supervised echocardiograms for the purpose of FCU with a V-
scan.91 The training scheme was based on a previous experience in neighbouring Fiji 
with a total of approximately 60 hours of training (combining lectures and supervised 
hands-on sessions).92 Consistently, these results are similar to this pilot study that 
assessed the feasibility of echo-screening by nurses using standard non portable 
equipment.92 As outlined by the American Society of Echocardiography and the 
European Society of Cardiology, standardization of training programs and proficiency 
are of outmost need before the widespread use of pocket-echo for FCU, especially for 
screening purposes by non-experts.93, 94 In the absence of such standardization, 
varying results may be obtained according to the skills and motivation of different 
health workers. There may be room for improvement in the proficiency of RHD 
screening by non-experts, possibly through the experience acquired in the field.65 
Lastly, simplified echocardiographic criteria were used for the diagnosis of RHD on-
site. Diagnostic criteria directly impact on the case-detection rates, which may partly 
explain the performance of the FCU strategy in the detection of RHD.95 The 
increasing interest in exploring echocardiographic detection of silent or subclinical 
RHD has led to the publication of standardized echocardiographic criteria.19, 47, 48, 53, 72 
In the lack of a gold standard for RHD diagnosis, the WHF criteria are of the outmost 
importance as a surrogate marker of the disease. Although based on the best level of 
evidence, the WHF criteria require experienced operators and readers since it includes 
the use of continuous Doppler and the analysis of morphological changes of the mitral 
and aortic valves.53 Morphological criteria appear to be of additional value in 
experienced hands with high-end equipment.95 However, preliminary data suggest 
that more simple criteria may carry acceptable sensitivity and specificity when it 
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comes to RHD detection.76, 96 This prospective evaluation demonstrates that complex 
diagnostic criteria is not applicable to pocket-echo, such as the analysis of 
morphological changes of the mitral valve, in line with a previous report.75 
Studies have so far systematically used a two-step diagnostic approach using high 
quality non-portable equipment and qualified cardiologists.19, 47-50, 72, 96 Although 
imperfect, the methods of this study explore ways of providing a diagnosis on site 
with no need for further testing or readings. Remoteness is a major barrier to 
healthcare delivery, especially in rural areas in developing countries. Therefore, a 
rapid diagnosis in school or in the community (without the need for further testing in 
hospital) seems most appropriate in the planning of active surveillance for RHD.  
 In addition, the performance of this FCU approach improves in the detection of 
definite RHD, with a sensitivity of almost 90%. Definite RHD requires secondary 
prophylaxis by penicillin for at least 10 years whilst borderline RHD should be 
offered regular follow-up.56 Indeed, some authors question the pathogenicity of 
borderline RHD although significantly more prevalent among children at risk of 
RHD.96, 97 High sensitivity for the detection of definite RHD is therefore crucial for 
the management of screened populations, whereas the interest of screening borderline 
RHD remains unclear. 
Further studies are needed in order to validate this strategy before being translated 
into public health policies. Cost-effectiveness analysis should however consider 
simplified strategies for active surveillance as the one described in this work. 
 
3.3.6. Conclusions 
 
Focused cardiac ultrasound with pocket-sized devices, operated by non-experts, 
through simple echocardiographic criteria, appears feasible and yields acceptable 
sensitivity and specificity for RHD detection when compared to the state-of-art 
approach. Focused cardiac ultrasound has the potential to provide a diagnosis on-site 
within minutes. However, echocardiography-based screening cannot be advocated for 
at this stage, and further evaluation is needed before implementation in countries 
where RHD remains endemic. 
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3.4.  Study 3. Symptomatic Rheumatic Heart Disease: estimated prevalence, 
characteristics and outcomes in New Caledonia 
 
3.4.1. Abstract  
Objectives. We aimed at assessing the prevalence, incidence, outcomes and 
influencing factors of RHD in the contemporary era. 
 
Methods. Hospital-based cohort of patients admitted with RHD according to WHF 
echocardiographic criteria were enrolled (2005-2013). The incidence of major 
cardiovascular events (MACE) including heart failure, peripheral embolism, stroke, 
heart valve intervention, and cardiovascular death was calculated, and their 
determinants identified.  
 
Results. Among the 1,142 patients identified, 831 validated WHF criteria for definite 
RHD. The estimated prevalence of definite RHD in New Caledonia was 2.80 per 
1,000 inhabitants (95% CI 2.60 –3.00) in 2013. Among Indigenous Melanesians the 
prevalence was 4.93 per 1,000 (95% CI 4.50-5.35). The annual incidence of RHD by 
WHF criteria was 2.08 per 10,000 person-years (95% CI 1.89-2.27) overall; and 3.68 
per 10,000 person-years (95% CI 3.28-4.08) in Indigenous Melanesians. A subset of 
396 patients had newly diagnosed RHD and quantification of left-sided valve disease; 
43.9% were male with median age 18 years [IQR 10-40]. 127 (32.1%) patients 
presented with mild, 131 (33.1%) with moderate, and 138 (34.8%) with severe heart 
valve disease. 205 (51.8%) had features of ARF. 106 (26.8%) presented with at least 
one major cardiovascular event. Among the remaining 290 patients, after a median 
follow-up period of 4.08 (95% CI 1.84-6.84) years, 7 patients (2.4%) died and 62 
(21.4%) had a first MACE. The annual incidence of first MACE and of heart failure 
was 59.05‰ (per 1,000) (95% CI 44.35-73.75), and 29.06‰  (95% CI19.29-38.82), 
respectively. The severity of RHD at diagnosis (moderate vs. mild HR 3.39 (0.95 – 
12.12); severe vs. mild RHD HR 10.81 (3.11 – 37.62), p<0.001), and ongoing 
secondary prophylaxis at follow-up (HR 0.27 (0.12-0.63), p=0.01) were the two most 
influential factors associated with MACE.  
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Conclusions. Rheumatic heart disease remains endemic in New Caledonia, especially 
among Indigenous Melanesians. Newly diagnosed RHD is associated with poor 
outcomes, mainly in patients with moderate or severe valve disease and no secondary 
prophylaxis.  
 
 
3.4.2. Introduction 
 
The burden of RHD is still a major challenge in the developing world with 
approximately 15-20 million people affected and 345,000 deaths per year 
worldwide.2, 5 The most recent available epidemiological data are mainly issued by 
echocardiography-based screening studies. This is somehow questionable given that 
the natural history of subclinical RHD still needs to be fully assessed. Hospital data 
may be valuable, especially when the catchment area comprises the entire region or 
country. In the case of this thesis both population-based and hospital-based data were 
available, providing a comprehensive picture of the epidemiology of RHD in New 
Caledonia. Multiple sources of data may validate, or not, the model incorporating 
symptomatic and asymptomatic RHD (Figure 1.4). 
In addition, there is limited contemporary data on the characteristics of patients with 
newly diagnosed RHD.16 Only a handful of clinical studies assessed predictors of 
outcomes in ARF and RHD either present a highly selected population,8 or date back 
to the 1950’s when access to interventions was extremely limited.42 The two 
contemporary hospital-based registers have so far described characteristics of patients 
with no or limited (up to 30 months) follow-up.16, 81  
In this section of the thesis are presented the results of a hospital-based cohort study.98 
The objective was twofold: to estimate prevalence and incident figures of RHD in 
New Caledonia; and to describe the characteristics and outcomes of patients with 
newly diagnosed RHD according to standardized and pre-specified diagnostic criteria. 
Another secondary objective was to assess factors associated with outcomes, focusing 
on patients with no major cardiovascular events at entry. 
 
3.4.3. Methods 
The methods of this study have been detailed in Section 2.4. of this thesis. 
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Briefly, potential participants were retrospectively identified through primary or 
secondary ICD 10 separation diagnosis of ARF or RHD of hospital admissions at 
CHT from January 1st 2005 to December 31st 2012. Patients were also prospectively 
identified in 2013. Patients were considered as suffering of definite RHD if they 
fulfilled the WHF criteria for “definite” RHD53. 
Specific attention was taken in the description of patients with newly diagnosed RHD 
(or incident RHD) for whom quantification of heart valve disease67 was available. 
Factors associated with outcomes were analysed in this subset of patients.  
 
3.4.4. Results  
 
Estimated prevalence and incidence of RHD in New Caledonia 
A total of 1,142 patients were identified. Among the 1,142 patients, 831 presented 
with WHF criteria for definite RHD, including 78 deaths between 2005 and 2013 
(Figure 3.9). The overall prevalence of RHD was 3.14 per 1,000 (95% CI 2.93-3.35). 
The estimated prevalence of RHD by WHF criteria in 2013 was of 2.80 per 1,000 
inhabitants (95% CI 2.60–3.00). The prevalence was higher in Indigenous 
Melanesians: 4.93 per 1,000 (95% CI 4.50-5.35). In children aged 9 and 10 years, the 
estimated prevalence rates were 1.43 (95% CI 0.29-2.57) and 1.59 (95% CI 0.41-
2.77) per 1,000, respectively.  
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Figure. 3.9. Flow chart of the hospital-based cohort. 
 
The annual incidence of RHD by WHF criteria was 2.08 per 10,000 person-years 
(95% CI 1.89-2.27) during the study period. The annual incidence of RHD over the 
study period is represented in Figure 3.10. The annual incidence of RHD revealed by 
ARF was overall 1.03 per 10,000 person- years, and 5.01 per 10,000 person-years in 
those under 15 years of age. The annual RHD incidence according to class-age and to 
the clinical presentation (with or no ARF) is depicted in Table 3.8.  
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Figure 3.10. Annual incidence of RHD by WHF criteria. 
 
 
Population Annual incidence of 
RHD by WHF criteria 
per 10,000 person years 
(95% CI) 
Annual incidence of 
RHD revealed by ARF 
per 10,000 person years 
(95% CI) 
Annual incidence of 
RHD with no ARF per 
10,000 person years 
(95% CI) 
Age <15 years 5.01 (4.27-5.74) 3.97 (3.31-4.62) 1.04 (0.71-1.38) 
Age 15-24 years 1.67 (1.24-2.10) 0.92 (0.60-1.24) 0.75 (0.46-1.04) 
Age 25-39 years 1.83 (1.46-2.20) 0.64 (0.42-0.86) 1.19 (0.89-1.49) 
Age ≥40 years 1.55 (1.29-1.82) 0.25 (0.14-0.36) 1.30 (1.06-1.55) 
Table 3.8. The annual RHD incidence according to age 
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Eighty-four children were diagnosed with symptomatic RHD and were 9-10 years old 
between 2008 and 2011. Table 3.9 compares hospital-based and population-based 
prevalence estimates in children aged 9-10 years. 
 
Year  Asymptomatic subclinical RHD 
prevalence per 1,000 [95% CI] 
Symptomatic RHD prevalence per 1,000 
[95% CI] 
2008 9.3 [6.3- 13.2] 1.97 [1.15-3.16] 
2009 6.5 [4.1- 9.6] 1.74 [0.97-2.87] 
2010 10.3 [7.4- 14.1] 3.13 (2.07-4.56] 
2011 9.9 [6.9- 13.7] 2.90 [1.88-4.28] 
Table 3.9. Annual prevalence of rheumatic heart disease in children aged 9-10 years 
by means of two data sources: systematic echocardiography-based screening for 
asymptomatic subclinical RHD, and hospital cohort for symptomatic RHD. 
 
Characteristics of patients with newly diagnosed RHD according to WHF criteria 
and valve disease quantification 
Among the 461 patients with newly diagnosed RHD, 396 patients had formal 
quantitation of heart valve disease. 174 (43.9%) were male with a median age of 18 
years (IQR 10-40). 274 (71.9%) were indigenous Melanesians, 85 (22.3%) were 
Polynesians, and 22 (5.8%) were of other ethnicity. 205 (51.8%) presented with ARF. 
Based on standardized echocardiograms, 127 (32.1%) patients had mild heart valve 
disease, 131 (33.1%) had moderate valve disease, and 138 (34.8%) had severe heart 
valve disease at the time of diagnosis. Mitral regurgitation was the most frequent 
heart valve disease, followed by aortic regurgitation and mitral stenosis. Multiple 
valve disease was present in 56.3% of cases. Moderate or severe tricuspid 
regurgitation was present in 4.5% of patients. 32 (8.1%) patients had permanent or 
paroxysmal atrial fibrillation. 37 (9.3%) patients had left ventricular ejection fraction 
under 60%.  
Among the 396 patients included, 106 (26.8%) presented with MACE at entry. There 
were 83/106 patients admitted with heart failure, among which: 12 leading to urgent 
valve intervention (i.e., within 30 days); 5 with concomitant stroke; and one with 
concomitant stroke and urgent intervention. In addition, 12/106 patients were 
admitted with stroke; 10/106 underwent urgent intervention; and one was admitted 
with stroke and underwent intervention.  
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Table 3.10. Characteristics of patients with newly diagnosed RHD. *Missing data in 
Characteristics at diagnosis 
 
All N=396 
Age, median (IQR) 18 (10-40) 
Male, n (%) 174 (43.9) 
Ethnicity* 
-Indigenous Melanesians 
-Polynesians  
-Other 
 
274 (71.9) 
85 (22.3) 
22 (5.8) 
Presentation with ARF 205 (51.8) 
Family history of RHD or ARF** 114 (60.6) 
Supra ventricular arrhythmias*** 32 (8.1) 
Initial left-sided valve disease on echocardiogram 
Mitral regurgitation, n (%) 
Nil 
Grade 1/4 
Grade 2/4 
Grade ≥ 3/4 
 
 
69 (17.4) 
162 (40.9) 
110 (27.8) 
55 (13.9) 
Mitral stenosis, n (%) 
Nil 
Mild 
Moderate 
Severe 
 
265 (66.9) 
42 (10.6) 
30 (7.6) 
59 (14.9) 
Aortic regurgitation, n (%) 
Nil 
Grade 1/4 
Grade 2/4 
Grade ≥3/4 
 
201 (50.8) 
109 (27.5) 
53 (13.4) 
33 (8.) 
Aortic stenosis, n (%) 
Nil 
Mild 
Moderate 
Severe 
 
370 (93.4) 
10 (2.5) 
9 (2.3) 
1 (0.5) 
Multiple left-sided valve disease, n (%) 223 (56.3) 
Overall severity of RHD§ 
-Mild 
-Moderate 
-Severe 
 
127 (32.1) 
131 (33.1) 
138 (34.8) 
Moderate or severe TR§§, n (%) 17 (4.5) 
LVEF<60%, n (%) 37 (9.3) 
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15 cases. **Up to 2nd degree relatives; missing data in 208 cases. ***Defined as 
paroxysmal or persistent atrial fibrillation, flutter or atrial tachycardia.  §Defined as 
mild RHD if single or multiple left sided valve disease graded as mild; moderate RHD 
defined as at least mitral or aortic moderate valve disease (regurgitation or stenosis); 
severe RHD defined as at least mitral or aortic severe valve disease (regurgitation or 
stenosis). §§Missing data in 22 cases. 
 
 
Outcomes and their determinants in patients with no major cardiovascular events at 
entry 
Patients with no MACE at presentation (N=290) were eligible for further analysis. 
Median age was 13 (IQR 10-31) years, 131 (45.2%) were male, and 185 (63.8%) 
presented with ARF. Patients with ARF were younger (p<0.01), had more often a 
family history of ARF (p=0.01), less atrial arrhythmias (p<0.01), and had different 
heart valve disease pattern (p<0.01) when compared to those with no ARF (Table 
3.11). 
 
The 290 patients were followed up for median 4.08 (95% CI 1.84-6.84) years. 
Overall, there were 62 MACE; the annual incidence of MACE was 59.05‰ (95% CI 
44.35-73.75); and median follow-up period to MACE was 10.49 (95% CI 2.04-35.03) 
months. Taken individually, the annual incidence of heart failure (34 patients) was 
29.06‰ (95% CI 19.29-38.82). The annual incidence of stroke was 7.26‰ (95% CI 
2.52-12.01). The survival rate was 97.89% (CI 95% 95.97-99.64) at 4 years, and 
96.21% (CI 95% 89.95-98.60) at 8 years after diagnosis. During the study period, 7 
patients (2.4%) died of whom 4 from cardiovascular death (i.e., incidence of RHD-
attributable mortality of 3.16 ‰ (95% CI 0.06-6.26) per year). Causes of 
cardiovascular death included: heart failure (N=2), stroke (N=1), and infective 
endocarditis (N=1).  Other events were noted during the study period: atrial 
fibrillation in 7 (2.4%), infective endocarditis in 8 (2.8%) patients, cardiogenic shock 
in 2 (0.70%), major hemorrhage in 8 (2.8%) patients. Among the 59 women in 
childbearing age (i.e., 15-45 years of age), 9 (15.2%) developed complications during 
subsequent pregnancies.  
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Table 3.11. Characteristics according to ARF status.  
 
 
 
 
 
 
Characteristics at diagnosis 
 
No ARF 
N=105 
ARF at presentation 
N=185 
All 
N=290 
P 
Age, median (IQR) 31 (15-47) 11 (9-15) 13 (10-31) <0.001 
Male, n (%) 43 (40.9) 88 (47.6) 131 (45.2) 0.3 
Ethnicity, n (%) 
-Indigenous Melanesians 
-Polynesians  
-Other 
 
73 (70.9) 
20 (19.4) 
10 (9.7) 
 
127 (71.7) 
43 (24.3) 
8 (4.5) 
 
200 (69.0) 
63 (21.7) 
18 (6.2) 
 
0.12 
Family history of RHD or ARF, n (%) 39 (56.5) 52 (76.5) 91 (66.4) 0.01 
Supra ventricular arrhythmias 7 (6.7) 0 (0.0) 7 (2.4) <0.001 
Initial left-sided valve disease on 
echocardiogram 
Mitral regurgitation, n (%) 
Nil 
Grade 1/4 
Grade 2/4 
Grade ≥ 3/4 
 
 
 
21 (20.0) 
44 (41.9) 
28 (26.7) 
12 (11.4) 
 
 
 
17 (9.2) 
91 (49.2) 
58 (31.3) 
19 (10.3) 
 
 
 
38 (13.1) 
135 (46.6) 
86 (29.7) 
31 (10.7) 
 
 
0.06 
-Mitral stenosis, n (%) 
Nil 
Mild 
Moderate 
Severe 
 
16 (15.2) 
14 (13.3) 
59 (56.2) 
16 (15.2) 
 
161 (87.0) 
15 (8.1) 
6 (3.2) 
3 (1.6) 
 
177 (61.0) 
29 (10.0) 
65 (22.4) 
19 (6.6) 
<0.001 
 
Aortic regurgitation, n (%) 
Nil 
Grade 1/4 
Grade 2/4 
Grade ≥3/4 
 
51 (48.6) 
23 (21.9) 
23 (21.9) 
8 (7.6) 
 
102 (55.1) 
69 (37.3) 
8 (4.3) 
6 (3.2) 
 
153 (52.8) 
92 (31.7) 
31 (10.7) 
14 (4.8) 
<0.001 
Aortic stenosis, n (%) 
Nil 
Mild 
Moderate 
Severe 
 
94 (89.5) 
5 (4.7) 
4 (3.8) 
2 (1.9) 
 
182 (98.4) 
1 (0.5) 
2 (1.1) 
0 (0.0) 
 
276 (95.2) 
6 (2.0) 
6 (2.0) 
2 (0.7) 
0.004 
Multiple left-sided valve disease, n (%) 70 (66.7) 81 (43.8) 151 (52.0) <0.001 
Overall severity of RHD 
-Mild 
-Moderate 
-Severe 
 
27 (25.7) 
44 (41.9) 
34 (32.4) 
 
97 (52.4) 
61 (33.0) 
27 (14.6) 
 
124 (42.8) 
105 (36.2) 
61 (21.0) 
 
<0.001 
Moderate or severe TR, n (%) 2 (2.0) 2 (1.1) 4 (1.4) 0.35 
LVEF<60%, n (%) 7 (6.7) 2 (1.1) 9 (3.1) 0.01 
PASP>35 mmHg, n (%) 13 (12.4) 8 (4.3) 21 (7.2) 0.01 
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Events Incidence per 1 000 persons year 
(95% CI) 
MACE 59.05 (44.35-73.75) 
Death 4.74 (0.95-8.54) 
Cardiovascular death 3.16 (0.06-6.26) 
Heart Failure 29.06 (19.29-38.82) 
Stroke 7.26 (2.52-12.01) 
Non-neurologic embolism 1.59 (0-3.78) 
Heart valve interventions 36.47 (25.17-47.77) 
Table 3.12. Incidence rates for MACE. 
 
Secondary prophylaxis was prescribed at least at one point in time during follow-up in 
235 (81.0%) patients. Continuation of secondary prophylaxis was reported in 159 out 
of 227 (70.0%) patients (missing data in 63 cases). The use of secondary prophylaxis 
at time of interview varied according to age (7.5% in patients aged>40 years; 94.7% 
in patients aged 5-20 years old).  
 
In addition to patients (24/396) in need for urgent heart valve interventions within 30 
days of diagnosis, 40 patients (13.8%) underwent either percutaneous or surgical 
procedures during the study period. The annual incidence of heart valve interventions 
was 36.47‰ (95% CI 25.17-47.77). Fifty-nine heart valve interventions were 
undertaken in these 40 (13.8%) patients, including 7 (2.4%) percutaneous mitral 
valvuloplasty; 5 (1.7%) mitral valve repair; 23 (7.9%) mitral valve replacement; 18 
(6.2%) aortic valve replacement.  
 
Factors included in the univariate analysis are described in Table 3.13. 
 
Characteristics significantly associated with MACE on multivariate analysis were: the 
severity of heart valve disease at diagnosis (moderate vs. mild HR 3.36 (95% CI 1.10 
– 10.34); severe vs. mild RHD 10.54 (95% CI 3.50 – 31.75), p<0.001), ARF at 
diagnosis (HR 0.46 (95% CI 0.24-0.89), p=0.02), and older age (21-40 vs. 5-20 years 
old, HR  2.88 (95% CI 1.34-6.22); over 40 vs. 5-20 years old, HR 5.15 (95% CI 2.44-
10.88), p<0.01).  
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Factor Univariate HR (95% CI) Univariate P value 
Mild RHD 
Moderate  RHD 
Severe RHD 
1 
8.1 (2.8-23.3) 
24.9 (8.8-70.8) 
<0.001 
ARF vs. no ARF 0.17 (0.09-0.30) <0.001 
Sex (male) 0.8 (0.5-1.3) 0.34 
Melanesian 0.6 (0.4-1.1) 0.09 
Age group 
5-20 yrs 
21-40 yrs  
>40 yrs 
 
1 
6.1 (2.9-12.41) 
15.2 (8.0-28.8) 
 
<0.001 
On-going secondary prophylaxis at FU 0.13 (0.07-0.23) <0.001 
Table  3.13. Univariate analysis of factors associated with MACE. 
 
 
 
Figure 3.11. Kaplan Meier survival free of MACE according to VHD severity. 
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Factor Multivariate HR (95% CI) Multivariate P value 
Mild RHD 
Moderate  RHD 
Severe RHD 
1 
3.36 (1.10 – 10.34) 
10.54 (3.50 – 31.75) 
<0.001 
ARF vs. no ARF 0.46 (0.24-0.89) 0.02 
Sex (male) 0.81 (0.48 - 1.36) 0.43 
Melanesian 0.66 (0.37-1.18) 0.16 
Age group 
5-20 yrs 
21-40 yrs  
>40 yrs 
 
1 
2.88 (1.34-6.22) 
5.15 (2.44-10.88) 
 
<0.001 
Table 3.14. Multivariate analysis of factors associated with MACE. 
 
After sensitivity analysis including secondary prophylaxis at the time of interview (63 
patients with missing information), two factors remained associated with outcomes: 
the severity of heart valve disease at diagnosis (moderate vs. mild HR 3.22 (0.90 – 
11.49); severe vs. mild RHD HR 11.07 (3.21 – 38.22), p<0.001), and on-going 
secondary prophylaxis at the time of interview (HR 0.33 (0.14-0.79), p=0.013). 
 
Factor Multivariate HR (95% CI) Multivariate P value 
Mild RHD 
Moderate  RHD 
Severe RHD 
1 
3.22 (0.90 – 11.49) 
11.07 (3.21 – 38.22) 
<0.001 
ARF vs. no ARF 0.54 (0.25-1.14) 0.10 
Sex (male) 0.82 (0.47 - 1.45) 0.50 
Melanesian 1.07 (0.54-2.13) 0.84 
Age group 
5-20 yrs 
21-40 yrs  
>40 yrs 
 
1 
1.97 (0.79-4.92) 
2.10 (0.72-6.10) 
 
0.31 
On-going secondary prophylaxis at 
follow-up. 
0.33 (0.14-0.79) 0.013 
Table 3.15. Sensitivity analysis of factors associated with MACE.  
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3.4.5. Discussion 
 
This study contributes to the current knowledge of RHD in two ways, by providing: 
epidemiological figures in New Caledonia; and data on outcomes. In addition to 
population-based figures driven by echocardiography screening in schoolchildren, this 
study confirms that RHD and ARF remain a significant health care issue in the 
Pacific, especially among Indigenous Melanesians. Unlike other studies, the incidence 
of RHD does not increase with age in this cohort. These findings may be explained by 
the overrepresentation of patients diagnosed during an ARF attack (half our patients 
presented with ARF) when compared to other settings. Nonetheless, a significant 
proportion of patients (~25%) are still diagnosed at the onset of complications and/or 
at a stage when heart valve interventions are urgently needed. The severity of heart 
valve disease was evenly distributed at presentation with one third having mild heart 
valve disease, one third moderate, and the remaining third severe heart valve disease. 
Approximately 20% needed heart valve intervention during the study period (median 
follow-up ~4 years). Survival rates were as high as 96% at median follow-up 4 years. 
The annual incidence of complications and RHD-related mortality is high even in 
young patients who are initially admitted with uncomplicated RHD (~59‰ per year). 
Factors associated with outcomes include: the severity of heart valve disease at 
diagnosis and continuation of secondary prophylaxis. Our results suggest that early 
diagnosis and secondary prophylaxis is cornerstone to reducing the burden of RHD. 
 
Rheumatic heart disease remains prevalent in New Caledonia based on hospital 
figures of well-characterised patterns of disease. The prevalence is higher among 
Indigenous Melanesians, in keeping with the results of study n°1. The hospital-based 
prevalence estimates in children aged 9-10 years were approximately threefold lower 
than figures driven from the echocardiography-based survey (~3 versus 10 per 1,000). 
These results are in keeping with the recently advanced model incorporating 
asymptomatic and symptomatic RHD.54 Indeed, a significant number of subclinical 
RHD may never lead to symptomatic disease and a large proportion of patients with 
RHD and a murmur may not present cardiovascular events. 
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Interestingly, ARF diagnosis appeared to be a major component in the detection of 
RHD. These results are encouraging since ARF diagnosis provides the opportunity to 
introduce secondary prophylaxis early and prevent complications. 
Although RHD still remains present in New Caledonia, the incidence of RHD and 
ARF is much lower than in other settings. Sliwa and colleagues reported figures as 
high as 235 per 10,000 person-years in South Africa in 2006-2007.16 Similarly the 
incidence of ARF is of approximately 200 per 100,000 person-years in Northern 
Australia.28 Hospital-based figures are subject to debate given the selection bias it 
implies. Sliwa and colleagues also estimated their figures from a hospital register.  
Also more stringent case definitions in this work (WHF criteria) may have led to 
more conservative figures. In the report by Lawrence, notification data was the major 
source with no verification of the accuracy of diagnosis.28 Although methods differed, 
the major differences between New Caledonia on the one hand, and South Africa and 
Australia on the other, suggest that these are truly related to the burden of the disease. 
Unlike reported in South-Africa,16 the incidence of RHD decreased with age, 
suggesting that ARF detection drives RHD diagnosis in New Caledonia. Indeed, it has 
been recommended that every child with ARF to be admitted to CHT in order to 
ensure appropriate testing and treatment. The magnitude of the problem related to 
RHD is not as high in New Caledonia as in other underprivileged and remote regions. 
 
Our study population is young and mainly indigenous, in keeping with population-
based studies in the region.28, 98, 99 The characteristics of our population are overall 
consistent with the two other RHD hospital-based registers published to this date.16, 81 
Half our patients had ARF, as in other upper-middle income settings.81 A history of 
ARF is more often reported in wealthier settings,81 suggesting the impact of health-
care services in the ability to diagnose the condition.100 The heart valve disease 
pattern is slightly different from that described in the heart of Soweto study,16 with a 
higher proportion of mild mitral and aortic regurgitation in our study, likely due to the 
inclusion of children and adolescents with ARF. Patients presenting with ARF were 
younger, with milder heart valve disease, less left ventricular impairment and 
pulmonary hypertension when compared to those with no ARF. 
Late diagnosis remains however a reality in many cases, revealed by the onset of 
complications in young and middle-aged adults. Almost one third present with major 
cardiovascular complications including: heart failure, stroke, non-neurological 
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embolism, or cardiovascular death. Furthermore, the incidence of heart failure was 
high in patients admitted with initially uncomplicated RHD (~30‰ per year), 
followed by stroke. Other complications included atrial fibrillation and haemorrhagic 
events. Maternal morbidity was also notable, in keeping with previous reports.101, 102 
Patients were at considerable risk of developing infective endocarditis, as suggested 
in a previous report focusing on Oceanic populations.103 
 
When restricted to patients with uncomplicated RHD at entry, we report mortality 
rates of 2.4% at median 4 years follow-up. Lawrence and colleagues recently reported 
crude all cause mortality rates of 3.9% at 5 years.28 Our results are therefore 
consistent with those from neighbouring Australia. However, mortality rates from 
New Caledonia and Australia, two high-income countries where patients have access 
to treatment, may not be transposable to resource poor settings, and should not lead to 
underestimating the global burden of the disease.2  
Patients with uncomplicated RHD remain at high risk of heart failure, 
thromboembolic events, and infective endocarditis. When combining all major 
cardiovascular events, the annual incidence is high (~59‰), considering the young 
age of our population.  
One fifth of our study population needed heart valve interventions during the study 
period. Of note, over one third of patients had severe valve disease and heart valve 
interventions may have been underused, as previously described in other settings.104 
The New Caledonian social security provides free of charge access to medical 
treatment and interventions. Invasive procedures may be carried out urgently with use 
of air-transport to the closest surgical centre (Sydney, Australia). Heart valve 
interventions are however not accessible in many countries where RHD remains 
endemic, especially in low-income countries.31, 105, 106  
 
Approximately 55% of the patients with newly diagnosed RHD were under secondary 
prophylaxis at follow-up. All these patients had been diagnosed with RHD less than 
ten years before follow-up.64 One fourth of these patients were however 40 years old 
or more in whom secondary prophylaxis was usually stopped. The majority of 
children and adolescents were on secondary prophylaxis at the time of interview. 
However, as in other hospital- or population-based registers, there is room for 
improvement in terms of adherence to guidelines.81, 83, 100 
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Two factors were associated with poor outcomes. The severity of valve disease at 
diagnosis is understandably associated with adverse events, such as heart failure28 or 
need of heart valve interventions.16 Continuation of secondary prophylaxis was 
associated with better outcomes. Patients diagnosed with RHD during an ARF attack 
presented better outcomes but this was not confirmed when adjusting for secondary 
prophylaxis. These results therefore stress the importance of early diagnosis, when 
heart valve disease is still mild, which bears excellent prognosis. Identifying children 
with ARF is an opportunity to limit the burden of disease. Our results may also 
suggest that screening for these mild but definite lesions in children under 20 years 
could be of interest in order to avoid disease progression and future complications.19, 
95 As stressed in the Mosi-o-Tunya call, there is urgent need to build ARF/RHD 
registers in endemic regions to detect the condition early and implement secondary 
prophylaxis.107  
 
 
3.4.6. Conclusions 
 
Rheumatic heart disease and ARF remain prevalent and incident in New Caledonia, 
especially among Indigenous Melanesians. However, the burden of the disease seems 
less than in other parts of the world. Newly diagnosed RHD is often revealed by ARF 
and/or by complications. Mortality is low but morbidity remains high, especially 
when heart valve disease is moderate or severe and in the absence of secondary 
prophylaxis. These results add to the limited data on the burden of RHD and should 
warrant early diagnosis when heart valve disease is still mild to introduce and 
continue secondary prophylaxis.   
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4. Summary and conclusions 
 
This thesis incorporated three linked studies to explore critical questions regarding the 
burden of asymptomatic and symptomatic rheumatic heart disease (RHD). This 
summary chapter lists the unique contributions made by these studies, presents 
implications for both policy and practice, and makes recommendations for future 
research. 
 
4.1. Principal findings 
 
The primary purpose of the thesis was to determine the outcomes of asymptomatic 
and symptomatic RHD. More specifically, this thesis provides epidemiological data 
on RHD by quantifying incidence and prevalence of the condition based on 
population and hospital-based cohorts. The work encapsulated in this thesis explored 
issues in the field of echocardiography-based screening for subclinical RHD in terms 
of feasibility and outcomes. Finally, outcomes of newly diagnosed symptomatic RHD 
and factors associated with poor outcomes could be identified. 
 
There are five principal findings from this series of studies. Firstly, the studies 
presented in this thesis contribute to the data on the global burden of the disease by 
providing accurate case definitions. The prevalence estimates derived from a hospital-
based cohort and from a nationwide school-based screening programme support the 
pyramid model of RHD epidemiology. Indeed, asymptomatic RHD is at least 
threefold more prevalent, and constitutes the base of the pyramid, with only a 
minority of cases being seen in hospital, often at the onset of symptoms, either acute 
rheumatic fever or when cardiovascular events occur. The figures driven from these 
two independent studies suggest that, although RHD still remains prevalent in New 
Caledonia, the burden is less than among other indigenous populations (e.g., 
neighbouring Australia) or in deprived regions (sub-Saharan Africa). 
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Populations at risk of RHD were identified through a nationwide screening 
programme. The translation of methods of echocardiography-based screening used for 
research purposes into public health policies demonstrated to bear significant 
limitations in terms of completeness. These results suggest that surveys should focus 
on populations at risk only and that more simple ways to detect RHD are warranted.  
 
Outcomes of children with asymptomatic RHD detected by echocardiography are 
variable although the majority of valve lesions persist with little clinical implications. 
Promiscuity is associated with the persistence of the condition. Rheumatic heart 
disease being a dynamic condition, a significant proportion of children at high risk of 
RHD with normal baseline echocardiograms may present with acute rheumatic fever 
or borderline lesions at 2 years of follow-up. These results suggest that a single 
screening point in the lifetime of children at risk may be insufficient for disease 
control. 
 
Having demonstrated that disease persists in most cases of asymptomatic 
echocardiography-detected RHD, more simple methods for RHD detection were 
explored. Focused cardiac ultrasound (FCU) performed and interpreted by nurses 
after a short training scheme using pocket-echocardiographic machines and simplified 
criteria appears to yield acceptable sensitivity and specificity for RHD detection. This 
method performs better (sensitivity ~90%) when focusing on definite RHD according 
to World Heart Federation criteria. 
 
Finally, outcomes of symptomatic RHD are depicted in a population with reliable 
surgical and mortality registers. A significant proportion of patients present at the 
onset of complications and/or at a stage when heart valve interventions are urgently 
needed. This is worrisome given the access to primary care in the country. The 
survival rate was of ~96% at 8 years in those with uncomplicated RHD at 
presentation. However, the incidence of major cardiovascular events was as high as 
59‰ annually in a young population. Factors associated with poor outcomes in the 
subset of patients with uncomplicated RHD at presentation were the severity of heart 
valve disease and discontinuation of secondary prophylaxis.  
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4.2. Implications for policy and practice 
 
The findings of this thesis may have important policy and clinical implications. 
Methods previously used in research for echocardiography-based screening cannot be 
translated into public health policies, due to implementation issues, especially at 
larger scales. A single screening point in the lifetime of children at risk is insufficient 
to prevent RHD given the dynamic nature of the disease. Targeting populations at risk 
is warranted.  
 
The natural history of asymptomatic RHD detected by systematic echocardiography is 
variable although the majority of these mild valve lesions persist over time. 
Considering factors as promiscuity may help in guiding treatment by identifying 
patients with non-reversible RHD.  
 
Focused cardiac ultrasound by non-experts using pocket-echocardiographic machines 
may be an alternate method for RHD screening. Although imperfect in terms of RHD 
detection, FCU may be easier to implement than WHF recommended methods. 
 
The persistence of symptomatic RHD in New Caledonia highlights the fact that this 
remains a public health issue among the indigenous population. A significant 
proportion of patients present at the onset of complications and/or with moderate to 
severe heart valve disease. These results prompt further action for RHD control and 
supports the initiatives taken by the Agence Sanitaire et Sociale de Nouvelle 
Calédonie to detect the condition at its early stages. 
 
Outcomes of patients with newly diagnosed uncomplicated RHD demonstrate that 
mortality data is insufficient to quantitate the burden of disease. The condition bears 
high risk for complications but acceptable mortality rates in settings where patients 
have access to treatment. Further effort should be put into the continuation and 
adherence to secondary prophylaxis. Patients at risk of major cardiovascular events 
may benefit from closer follow-up and early interventions. 
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4.3. Implications for future research 
 
These findings should promote research in the field of echocardiography-based RHD 
screening not only in terms of imaging methods but also in public health 
implementation including cost-effectiveness of systematic screening.  
 
Although asymptomatic RHD mostly persists over time, longer follow-up periods 
may be needed to fully address the significance of subclinical asymptomatic RHD and 
the need for secondary prophylaxis in borderline RHD. 
 
Focused cardiac ultrasound has gained interest from other groups in the RHD field 
and larger scale studies would enable to validate, or not, this method in a variety of 
settings with different underlying RHD phenotypes and variable skilled healthcare 
workers. 
 
Longitudinal data are needed in New Caledonia in order to test the efficacy of public 
health policies including systematic screening of schoolchildren in terms of RHD 
prevalence and its outcomes. 
 
In conclusion, the findings of this thesis have addressed key questions regarding the 
outcomes of asymptomatic and symptomatic RHD. These results may set the scene 
for further comprehensive studies of asymptomatic and symptomatic RHD while 
providing key datasets to affect and influence policy. 
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5. Résumé de la thèse en langue française 
 
5.1. Introduction 
 
La cardiopathie rhumatismale (CR) demeure la première cause de cardiopathie 
acquise chez les enfants et les jeunes adultes à travers le Monde en raison de sa 
prévalence encore élevée dans les pays en voie de développement et parmi les 
populations aborigènes de certains pays développés.  
La CR est la séquelle de l’atteinte cardiaque du rhumatisme articulaire aigu (RAA), 
syndrome auto-immun post-infectieux. Il s’agit classiquement d’une angine à 
Streptocoque du groupe A qui induit chez l’hôte une réaction immunitaire 
inappropriée. Le RAA peut affecter différents organes avec une présentation clinique 
variable, la cardite survenant dans 2/3 des cas. La CR résulte le plus souvent d’accès 
répétés de RAA. Le dépistage précoce de la maladie est une stratégie attractive 
permettant de traiter par antibioprophylaxie les enfants avant l’aggravation des lésions 
valvulaires. Dans ce contexte, l’échocardiographie apparaît comme un outil de 
dépistage performant pour la détection précoce des lésions valvulaires rhumatismales. 
Le concept de CR « infraclinique » est d’abord apparu chez des patients atteints de 
RAA, pour s’étendre aux populations à risque (c’est-à-dire résidant en zone 
d’endémie). Malgré le nombre croissant d’études démontrant l’intérêt de 
l’échographie cardiaque dans le dépistage précoce, certaines questions demeurent en 
suspends. La valeur pronostique de ces lésions valvulaires minimes reste à démontrer. 
Aussi est-il question des méthodes de dépistage, car celles utilisées dans le cadre de la 
recherche nécessitent des appareils onéreux et une expertise technique.  
Les travaux que consitutent cette thèse s’efforcent de répondre à certaines de ces 
questions, en décrivant le pronostic de la CR symptomatique, et asymptomatique 
dépistée par échographie, ainsi que des méthodes simplifiées de dépistage 
échocardiographique. Trois études originales ont été menées dans le cadre de cette 
thèse et sont présentées ici. La version complète est disponible en langue anglaise. 
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5.2. Matériels et Méthodes 
 
5.2.1. Données sociodémographiques, économiques et sanitaires en Nouvelle 
Calédonie 
 
La Nouvelle-Calédonie archipel de l'océan Pacifique Sud, est Pays d’Outre Mer 
français. Sa population se chiffre à 268 767 habitants.108 La répartition de la 
population calédonienne par communauté d’appartenance est : mélanésienne pour 
40%, européenne pour 29%, wallisienne ou futurienne pour 9%, métisse pour 8%, et 
autre pour 7% de la population. Il s’agit d’un pays à revenus élevé, avec un produit 
intérieur brut (PIB) par habitant de 26 654 euros (33ème au rang mondial). Il existe des 
disparités ethniques dans la répartition des richesses. Les provinces Nord et des Îles 
Loyauté, qui comptent une population majoritairement mélanésienne, ont un revenu 
médian 2 à 2,5 fois moindre par rapport à la Province Sud où réside une majorité 
d'européens. 
La densité médicale en Nouvelle-Calédonie est de 223 médecins pour 100 000 
habitants. Il existe une disparité importante entre le Nord et le Sud avec une densité 
médicale de 274/ 100 000 dans le Sud contre 96/ 100 000 dans le nord et 80 / 100 000 
dans les îles Loyauté. 
Le Centre Hospitalier Territorial de Nouvelle Calédonie (CHT) est le seul centre 
teriaire de l’archipel pourvoyeur de soins spécialisés dans le pays. Les patients sont 
évacués soit vers la Métropole, soit vers l’Australie pour les interventions valvulaires. 
L’accès aux soins de proximité est assuré par des centres médico-sociaux dans 
chacune des communes.  
L’Agence Saniatire et Sociale de Nouvelle Calédonie (ASS-NC) coordonne les 
politiques de prévention des maladies non transmissibles. L’ASS-NC a mis en place 
une vaste campagne de dépistage de la CR par l’échographie cardiaque systématique 
ciblant tous les enfants scolarisés en classe de CM1 (âge attendu 9-10 ans) en 2008 et 
tient un registre d’antibioprophylaxie secondaire à l’échelle nationale. Il existe en 
outre un Département des Evacuations Sanitaires (EVASAN) dont la mission est, 
entre autres, de prendre en charge toute évacuation pour des interventions valvulaires 
cardiaques. En outre, un registre de mortalité nationale est tenu par le Département 
des Affaires Sanitaires et Sociales (DASS). 
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5.2.2. Materiel et Méthodes de l’étude n°1: évaluation des campagnes de 
dépistage écho-guidées et devenir des enfants sans et avec Cardiopathie 
Rhumatismale infraclinique 
 
Campagnes de dépistage écho-guidées en Nouvelle Calédonie 
Des campagnes annuelles de dépistage systématique visent tous les enfants scolarisés 
en classe de CM1 en Nouvelle Calédonie. Elles ont été mises en place en 2008 après 
une étude pilote menée en 2007. Après avoir obtenu l’autorisation des institutions de 
tutelle, une information est menée auprès des enfants et de leurs parents. Tous les 
enfants ayant une autorisation parentale participent au dépistage. Celui-ci se déroule 
en deux temps. Une première échographie (échographe portable VIVID I) réalisée par 
un médecin à l’école statue sur la normalité ou la suspicion de pathologie. Le 
diagnostic n’est porté que sur un deuxième examen réalisé sur un échographe non 
portatif par l’un des cardiologues participant au programme. Les critères 
diagnostiques ont été préalablement établis par le groupe de travail et sont proches de 
ceux de l’Organisation Mondiale pour la Santé (OMS) et de ceux publiés en 2012 par 
la Fédération Mondiale du Cœur (World Heart Federation, WHF).  
Tous les enfants diagnostiqués comme porteurs de CR ont été inclus dans le registre 
d’antibioprophylaxie et ont été pris en charge à 100% par le système de sécurité 
sociale néo-calédonienne.  
 
Objectifs 
Les objectifs de cette étude sont triples : 
• d’évaluer la première campagne de dépistage écho-guidée de la CR à l’échelle 
nationale 
• d’estimer la prévalence de la CR dans la population ciblée par les campagnes 
de dépistage 
• de suivre une cohorte d’enfants sans et avec CR 
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Méthodologie de l’étude de cohorte 
Etude de cohorte rétrospective issue des campagnes de dépistage de 2008 à 2011 
inclus. Suivi réalisé en 2012.  
Critères d’inclusion : tous les cas de CR étaient eligibles. Les non-cas de CR ont été 
choisis de façon aléatoire, appariés aux cas de CR selon l’ethnie et par classe d’école. 
Deux non-cas ont été tirés au sort par cas. 
Critères d’exclusion : diagnostic alternatif lors d’examens de suivi (cardiopathie 
congénitale). 
Données collectées : charactéristiques socio-démographiques ; valvulopathie et sa 
sévérité initiales ;  données échographiques et cliniques au suivi. 
 
Protocoles d’échographie 
L’échographie initiale a été menée sur un appareil portable (VIVID I, GE®) selon un 
protocole et des critères diagnostiques prédéfinis. Les images initiales n’ont pas été 
systématiquement sauvegardées. 
L’échographie de suivi a été réalisée sur le même appareil, soit au siège de l’ASS-NC, 
soit dans les centres de soins de proximité. L’acquisition des images a suivi un 
protocole prédéfini et le diagnostic porté lors de la relecture des examens anonymisés 
(sans connaître le statut cas/non-cas) par la doctorante selon les critères de la WHF.  
 
Reccueil des données au suivi 
Outre des données socio-démographiques et économiques supplémentaires, la 
présence d’un souffle pathologique (avant l’échographie), la survenue d’événements 
cliniques (épisode de RAA ou complications), le recours à l’antibioprophylaxie et ses 
modalités ont été colligées. Le registre de mortalité et le service des admissions du 
CHT ont été consultés pour les perdus de vue. 
 
Biais de l’étude 
Cette étude comporte un certain nombre de biais en partie liés à son caractère 
rétrospectif. Premièrement les critères diagnostiques, quoique similaires, ont changé 
au cours de l’étude. S’agissant d’un programme de dépistage à large échelle, les 
examens n’avaient pas été systématiquement sauvegardés et une réatribution du 
diagnostic n’a donc pas pu être conduite.  
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5.2.3. Materiel et Méthodes de l’étude n°2: évaluation d’une méthode simplifiée 
de dépistage écho-guidé de la Cardiopathie Rhumatismale 
 
Définitions 
Echographie de référence : échographie réalisée par un cardiologue et diagnostic porté 
par un expert (doctorante) après relecture en aveugle des échographies en utilisant les 
critères de la WHF. 
Méthode simplifiée : échoscopie réalisée et interprétée par un(e) infirmier(ère) naïf en 
échographie en utilisant un algorithme simplifié à l’aide d’échographes de poche, 
après une formation courte. 
 
Objectifs 
L’étude comporte deux parties avec des objectifs différents : 
Partie n°1 : identifier les critères diagnostiques simplifiés pour le diagnostic de CR en 
les comparant aux critères de référence de la WHF dans une population sélectionnée. 
Partie n°2 : tester la performance de ces critères diagnostiques à l’aide d’échographes 
de poche par des non-experts en situation de dépistage à l’école au sein d’une 
population à prévalence plus basse que lors de la Partie n°1. 
 
Méthodologie de l’étude. Il s’agit d’une étude prospective conduite en deux parties.  
 
Participants 
Partie n°1 : des enfants issus des années précédentes des campagnes de dépistage, 
sans et avec CR, ont été sollicités afin de participer à cette phase pilote en février et 
mars 2013.  
Partie n°2 : des enfants participant au dépsitage scolaire annuel de la CR conduite par 
l’ASS-NC à Nouméa se sont vus proposer de participer à l’étude entre avril et juillet 
2013. 
 
Protocole d’échographie 
Chaque participant a eu 3 échographies par 3 opérateurs différents (un cardiologue ; 
deux par des infirmières) dans un ordre aléatoire, chaque opérateur étant en aveugle 
par rapport aux données du participant et aux résultats des autres opérateurs. 
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L’échographie de référence a été menée suivant un protocole d’acquisition d’images 
prédéfini à l’aide d’un échographie portable VIVID I (GE®). 
L’échoscopie comportait le même protocole d’acquisition des images, le diagnostic 
étant porté à la fin de l’acquisition des images sur les mesures faites par l’infirmier 
(ère) sur un échographe de poche Vscan (GE®).  
Les critères testés lors de la 1ère partie de l’étude étaient: (i) la présence d’un jet 
d’insuffisance mitrale (IM) ; (ii) la présence d’un jet d’insuffisance aortique (IA) ; 
(iii) la reconnaissance d’anomalies morphologiques (cf. critères WHF Méthodes) ; 
(iv) la présence d’un jet d’IM de longueur ≥2cm ;  (v) la présence d’un jet d’IM de 
longueur ≥1,5cm ; la combinaison d’un jet d’IM ≥2cm et d’une IAo. 
 
Formation à l’échoscopie 
La formation a comporté 3 jours de cours théoriques suivis de 30 heures de stage avec 
un ratio instructeur/apprenant de 1 pour 2. Les objectifs pédagogiques ont porté sur: la 
reconnaissance des structures cardiaques ; l’acquisition des coupes parasternale grand 
et petit axe, apicale 4, 3 et 2 cavités et l’utilisation du Doppler couleur ; la 
reconnaissance d’anomalies morphologiques mitrale et aortique évocatrices de CR ; la 
reconnaissance des jets d’IM et d’IAo; la mesure de la longueur de jets d’IM et d’IAo. 
La formation a été complétée par la relecture et la réinterprétation de 50 des examens 
réalisés lors de la première partie. Un stage supplémentaire d’acquisition des images 
de 12 heures a également été mis en place. Cette formation complémentaire était sous 
la forme du tutorat de 1 :1.  
 
5.2.4. Materiel et Méthodes de l’étude n°3: estimation de la prévalence, de 
l’incidence et pronostic de la Cardiopathie Rhumatismale symptomatique 
 
Objectifs : Estimer la prévalence et l’incidence de la CR symptomatique en Nouvelle 
Calédonie ; décrire les caractéristiques et le pronostic des patients hospitalisés pour 
CR et identifier des facteurs associés à la survenue d’événement(s) sous la forme d’un 
critère composite (insuffisance cardiaque, accident vasculaire cérébral, embolie 
périphérique, intervention valvulaire, décès cardiovasculaire). 
 
Méthodologie : Etude rétrospective de cohorte hospitalière. 
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Participants : Les participants potentiels ont été identifiés via le Dapartement 
d’informatique médicale du CHT à l’aide de codes diagnostiques de RAA et de CR de 
2005 à 2012. Les patients admis en 2013 ont été inclus prospectivement.  
Critères d’inclusion : validation des critères échographiques de la WHF pour le 
diagnostic de CR certaine. 
Une étude ancillaire porte sur le groupe de patients nouvellement diagnostiqués de 
CR et sans complication à l’admission afin d’identifier les facteurs associés à la 
survenue d’événements. 
Un suivi centralisé a été mené entre mars et décembre 2013. Le registre de mortalité 
de la DASS et le bureau des EVASAN ont été consultés pour les patients perdus de 
vue. 
 
Données recueillies 
Les données socio-démographiques, les caractériques de la valvulopathie et sa 
quantification, la présence d’une poussée de RAA et la survenue de complications ont 
été recuillies au moment du diagnostic. Les événements indésirables suivants ont été 
colligés lors du suivi : insuffisance cardiaque définie par un stade NYHA III ou IV, 
l’embolie périphérique, l’accident vasculaire cérébral, l’intervention valvulaire, le 
décès cardiovasculaire. Les traitements dont le recours à l’antibioprophylaxie ont 
également été colligés. Le registre national d’antibioprophylaxie tenu par l’ASS-NC a 
été conuslté en cas de donnée manquante. 
 
5.2.5. Méthodes statistiques pour l’ensemble des études 
Les variables descriptives sont présentées avec leur moyenne ± dérivation standard 
(SD) ou médiane et intervalle interquartile. La comparaison des variables continues a 
été réalisée par le t-test de Student. Les variables discontinues ont été comparées par 
le test du Chi-2. Pour les étude n°1 et n°3 les prévalences ont été calculées avec un 
intervalle de confiance (IC) de 95% avec comme référentiel les données 
démographiques de l’ISEE; les données d'incidence sont expirmées par 10 0000 
personnes années. Pour les analyses de facteurs prédisposant à la présence ou à la 
persistance de la CR des Odds Ratio et Hazard Ratio ont été calculés avec leurs IC de 
95%. L’évaluation de la variabilité inter-observateur a été conduite par le test kappa 
ou le pourcentage de concordance pour l’étude n°2.  Le risque de survenue 
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d’événements dans l’étude n°3 été a été analysé par la méthode de Kaplan Meier. Un 
modèle de Cox univarié puis multivarié a également été conduit, avec un analyse de 
sensibilité en raison de données manquantes. Toutes les analyses ont été ajustées sur 
l’âge et le sexe. Les patients suivis et perdus de vue ont été comparés via les tests de 
Mann-Whitney (pour les variables quantitatives non paramétriques), de Fisher (pour 
les variables quantitatives paramétriques), et le test du chi-deux de Pearson (pour les 
variables qualitatives). Un seuil p < 0,05 a été considéré comme significatif. Les 
logiciels SAS 9.3 et 9.4® ont été utilisés pour l’ensemble des analyses statistiques. 
 
5.2.6. Considérations éthiques 
Les autorisations des comités de protection des personnes de Bordeaux Outre-Mer ont 
été obtenues pour les 3 études. Le comité d’éthique du CHT a validé l’étude n°3. Les 
parents ou tuteurs des participants aux études n°1 et 2 ont donné leur consentement 
écrit. Les participants à l’étude n°3 ont été informés oralement de la réalisation de 
l’étude lors du suivi, le comité d’éthique dispensant d’un accord écrit pour cette étude 
observationnelle. 
 
5.3. Résultats 
 
5.3.1. Etude n°1: évaluation des campagnes de dépistage écho-guidées et devenir 
des enfants sans et avec CR infraclinique 
 
Exhaustivité de la première campagne de dépistage écho-guidée de la CR à 
l’échelle nationale   
Parmi les 18 621 enfants ciblés par les campagnes de dépistage entre 2008 et 2011, 
soit 82,1% de la population néocalédonienne née entre 1998 et 2002, 858 (4,6%) 
étaient absents le jour du dépistage. Parmi les 17 287 participant au dépistage, 1 619 
(9,4%) ont été adressés pour une échographie de confirmation dont 418 (25,8%) ne se 
sont pas présentés. 
Cent cinquante-sept enfants ont finalement été diagnostiqués comme porteurs de CR, 
soit une prevalence de 9,5 pour 1 000 (IC 95% 8,1-11,1). La prevalence était 
significativement plus élevée chez les enfants âgés de 11 ans ou plus (p=0,004), les 
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océaniens (p<0,0001) et ceux résidant dans les Provinces Nord et Iles Loyauté 
(p<0,0001). 
 
Pronostic des lésions de CR asymptomatiques dépistées par échocardiographie 
Parmi les 157 enfants dépistés entre 2008 et 2011, 114 ont participé à l’étude, 
conjointement à 227 non cas (soit des enfants ayant des échographies considérées 
normales lors du dépistage). L’âge moyen au moment du dépsitage était de 9,9±0,7 
années dans le groupe CR et de 10,0±0,7 dans le groupe non-CR, avec un sexe-ratio 
(M/F) de 0,9 dans le groupe CR et de 1,0 dans le groupe non-CR. Les 114 enfants 
avec CR présentaient initialement les lésions valvulaires suivantes : insuffisance 
mitrale (IM) chez 107 (93,9%) cas, insuffisance aortique (IA) chez 34 (29,8%) cas, et 
sténose mitrale chez 6 (5,2%) cas. Une atteinte mitrale et aortique était présente chez 
30 (26,3%) cas. 
La durée médiane de suivi était de 2,58 années [IQR 1.31-3.63]. L’incidence annuelle 
de RAA était de 10,28 pour 1 000 chez les enfants ayant une CR dépistée par 
échographie. Un des enfants (0,9%) a présenté une complication clinique 
(insuffisance cardiaque) au cours du suivi. Aucune intervention valvulaire ni décès 
n’a été rapporté lors du suivi.  Cent un (88,6%) enfants se sont vu prescrire une 
antibioprophylaxie secondaire par pénicilline injectable. 
Parmi les 114 cas de CR, 41 (36,0%) avaient une CR certaine sur l’échographie de 
suivi, 49 (43,0%) avaient des lésions compatibles avec une CR limite, et 24 (21,1%) 
avaient une échographie dans les limites de la normale selon les critères WHF. Le 
facteur associé à la persistance de CR (certaine et limite) par analyse multivariée 
straitifée selon l’âge était le nombre de personnes par chambre (< 3 vs. ≥ 3, OR 8,27 
IC 95% (1,67-41,08), p<0,01).  Cette association demeurait significative lorsque les 
cas de CR limite étaient exclus de l’analyse (OR 7,70 IC 95% (1,28-46,45), p=0,03). 
Il n’y avait pas d’association significative entre la persistance des lésions et la 
compliance à l’antibioprophylaxie, définie comme une injection à intervalles 
inférieurs ou égaux à 4 semaines (p=0,78). 
L’incidence annuelle de RAA chez les enfants non atteints de CR était de 3,31 pour 
1000, ce qui n’était pas significativement différent des participants avec CR préalable 
(p=0,23). Parmi les 227 enfants avec échographie normale à l’état basal, 189 (89,3%) 
gardaient une échographie normale au suivi, 2 (0,9%) avaient une CR certaine et 29 
(12,8%) avaient une CR limite.  
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5.3.2. Etude n°2 : évaluation d’une méthode simplifiée de dépistage écho-guidé 
de la Cardiopathie Rhumatismale 
 
Partie n°1 : Identification de critères simplifiés pour l’échoscopie de dépsitage de la 
CR 
En mars 2013, 189 participants ont été inclus dans cette phase préliminaire. L’âge 
moyen des participants était de 12,2 (0,2) ans et 84 (44,4%) étaient de sexe masculin. 
Cent six (56,1%) enfants avaient des lésions de CR (63 CR certaine, 43 CR limite) et 
83 (43,9%) avaient une échographie normale. 
La sensibilité et la spécificité des 6 critères testés par les infirmiers à l’aide de 
l’échographe de poche étaient variables en comparaison à la méthode de référence. 
Parmi les 6 critères testés, la présence d’un jet d’IM ≥2cm ou d’une IA quelle que soit 
la longueur avaient une sensibilité de 76.4% (IC 95% 67,4-83,5) et de 70.7% (IC 95%  
61,4-78,6) pour chacun des infirmiers. La spécificité était de 73,5% (IC 95% 63.0-
70.7) et de 69,9% (IC 95% 59,2-69,1) pour chaucn des infirmiers. 
 
Partie n°2 : Evaluation de l’échoscopie utilisant le critère composite (IM ≥2cm ou IA) 
pour le dépistage de la CR en population scolaire 
Le nombre de participants à cette deuxième phase a été de 1 217 (âge moyen 9,6 (0,5) 
années, 603 (49,6%) de sexe masculin). Un diagnostic de CR a été porté chez 49 
(4,0%) des participants : 34 cas de CR limite, 15 cas de CR certaine. La sensibilité de 
l’échoscopie était de 83,7% (IC 95% 70,7-91,6) et de 77,6% (IC 95% 63,9-87,1) ; et 
la spécificté de 90,9% (IC 95% 89,1-92,4) et 92,0% (IC 95% 90,3-93,4) selon 
l’opérateur. La concordance des deux opérateurs était de 91,4%. Lorsque restreint aux 
cas de CR certaine, la sensibilité était de 93,3% (IC 95% 64,7-99,1) et 86.7% (IC 95% 
59,5-96,7). 
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5.3.3. Etude n°3 : estimation de la prévalence, de l’incidence et du pronostic de la 
Cardiopathie Rhumatismale symptomatique 
 
Epidémiologie de la CR symptomatique en Nouvelle Calédonie 
De façon globale en Nouvelle Calédonie, la prévalence de la CR définie par les 
critères de CR certaine de la WHF était de 2,8 pour 1 000 (IC 95% 2,60-3,00) en 
2013. Lorsque restreint à la population mélanésienne, la prévalence en 2013 était de 
4,93 pour 1 000 (IC 95% 4,50-5,35). Celle-ci était de 1,43 (IC 95% 0,29-2,57) à 1,59 
(IC 95% 0,412,77) pour 1 000 chez les enfants âgés de 9 et 10 ans, respectivemet. 
L’incidence annuelle moyenne de CR certaine était de 2,08 pour 10000 (IC 95% 1,89-
2,27) personnes-années, sans variation au cours de la période de l’étude.  
 
Pronostic de la CR symptomatique nouvellement diagnostiquée 
Parmi les 461 patients admis au CHT avec CR ou RAA, 396 remplissaient les critères 
d’inclusion de l’étude évaluant le pronostique, à savoir : CR certaine incidente (2005-
2013) selon les critères WHF avec quantification de la valvulopathie. 174 (43,9%) 
patients étaient de sexe masculin avec un âge médian de 18 (IQR 10-40) années. 274 
(71,9%) étaient Mélanésiens, 85 (22,3%) Polynésiens et 22 (5,8%) d’autre 
communauté d’appartenance. 205 (51,8%) étaient admis pour RAA. Sur 
l’échographie diagnostique, 127 (32,1%) patients avaient une valvulopathie modérée, 
131 (33,1%) moyenne et 138 (34,8%) sévère. Parmi les 396 patients inclus, 106 
(26,8%) s’étaient présentés à l’occasion d’une complication correspondant soit à de 
l’insuffisance cardiaque (stade NYHA III ou IV), à une embolie périphérique, à un 
accident vasculaire cérébral, à la nécessité de recourir urgemment à une intervention 
valvulaire ou au décès cardiovasculaire. L’analyse visant à identifier des facteurs 
associés à la survenue d’événements sous la forme d’un critère composite a porté sur 
les 290 patients sans événement initial. Parmi ces 290 patients, l’âge médian était de 
13 (IQR 10-31) années, 131 (45,2%) étaient de sexe masculin et 185 (63,8%) étaient 
diagnostiqués lors d’un accès de RAA. Ces 290 patents ont été suivis pendant une 
durée médiane de 4,08 (IC 95% 1,84-6,84) années. Il y a eu 62 événements pendant la 
durée de l’étude. Le taux de survie était de 97,89% (95% 95,97-99,4) à 4 ans et de 
96,21% (95% IC 89,95-98,60) à 8 ans.  L’incidence annuelle de l’événement 
composite était de 59,05‰ (IC 95% 44,35-73,75); avec une incidence annuelle 
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d’insuffisance cardiaque de 29,06‰ (IC 95% 19,29-38,82); d’accident vasculaire 
cerebral de 7,26‰ (IC 95% 2,52-12,01); et d’intervention valvulaire de 36,47‰ (IC 
95% 25,17-47,77). Lors de l’analyse de sensibilité incluant les patients avec données 
sur l’antibioprpohylaxie secondaire, deux facteurs étaient associés à la survenue de 
l’événement composite: la sévérité de la valvulopathie sous-jacente à l’échographie 
initiale (valvulopathie moyenne versus modérée HR 3,22 (0,90 – 11,49); 
valvuloapthie severe versus modérée HR 11,07 (3,21 – 38,22), p<0.001); et 
l’antibioprophylaxie secondaire par pénicilline au moment du suivi (HR 0,33 (0,14-
0,79), p=0,013). 
 
5.4. Discussion 
 
Les trois études présentées ici, disponibles dans leur intégralité dans la version 
anglaise de cette thèse, ont permis d’accroître les connaissances épidémiologiques de 
la CR en Nouvelle Calédonie. De façon plus large, elles ont eu comme objectif de 
répondre à certaines des questions dans le domaine dans le but de guider des 
politiques de santé publique futures dans les pays où la CR demeure endémique. 
 
La première étude a démontré les difficultés à mettre en œuvre des campagnes de 
dépistage écho-guidées de la CR à l’échelle nationale. Une proportion importante de 
la population ciblée échappe au dépistage en milieu scolaire et un quart de ceux 
suspects de CR n’ont pas de diagnostic finalement posé, ne se présentant pas au 
rendez-vous de l’échographie de confirmation. Il paraît ainsi que la méthodologie 
utilisée dans les travaux de recherche n’est pas directement transposable en termes de 
santé publique. Aussi, seule une partie de la population calédonienne est à risque de 
CR. Cibler les enfants océaniens par des campagnes répétées avec un diagnostic posé 
à l’école permettrait d’optimiser l’efficacité de cette politique de santé publique. 
Le suivi de la cohorte d’enfants sans et avec CR a permis d’apporter des informations 
pronostiques. La CR asymptomatique dépistée par l’échographie a un pronostic 
favorable à court terme, avec une persistance de lésions minimes dans la majorité des 
cas et peu d’événements cliniques. La promiscuité est un facteur associé à la 
persistance des lésions échographiques. En revanche, les enfants océaniens sans CR à 
l’âge de 9-10 ans ont un risque non négligeable de présenter soit un accès de RAA, 
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soit des lésions valvulaires échographiques à seulement 2 ans du dépistage négatif 
initial. Ces réusltats soulèvent des questions quant à l’âge de dépistage choisi en 
Nouvelle Calédonie et à l’intérêt éventuel de conduire des dépistages répétés au cours 
de l’adolescence au sein des populations à risque. 
 
La deuxième étude est le prolongement de la première, visant à tester des méthodes de 
dépistage simplifié de la CR à l’aide de l’échoscopie cardiaque par des non-experts en 
utilisant des échographes de poche et un algorithme diagnostique adapté. Les résultats 
sont en faveur d’une sensibilité et d’une spécificité acceptables de cette méthode pour 
la détection de la CR asymptomatique. La sensibilité est meilleure, de l’ordre de 90%, 
lorsqu’on vise à dépsiter les enfants porteurs de CR certaine uniquement, seul cas de 
figure où l’antibioprophylaxie est recommandée. Quoiqu’imparfaits, ces résultats 
ouvrent la voie à d’autres études devant l’intérêt potentiel comme outils de dépistage 
de masse dans les pays en voie de développement où les ressources consacrées à la 
prévention de la CR sont limitées. 
 
La troisième étude a permis d’asseoir les données épidémiologiques de la première. 
La CR demeure un fléau au sein de la population mélanésienne de Nouvelle 
Calédonie, sans diminution de l’incidence de 2005 à 2013. L’estimation de la 
prévalence à partir de cette cohorte hospitalière permet d’asseoir la continuité entre la 
CR asymptomatique dépistée par échographie et la CR symptomatique. Cette étude a 
permis en outre de décrire les caractéristiques des patients admis à l’hôpital avec une 
CR symptomatique. Quoiqu’encore endémique au sein de la population autochtone, la 
prévalance et l’incidence de la CR paraissent inférieures à celle rapportée en Australie 
ou en Afrique du Sud. Une proportion importante de nouveaux cas (~27%) se 
présente à l’occasion d’une complication alors que le système de soins de proximité 
donnerait en théorie la possibilité d’un diagnostic plus précoce. La mortalité à 8 ans 
parmi les patients avec une CR nouvellement diagnostiquée et sans complication 
initiale est basse mais l’incidence annuelle d’événements est élevée (~59‰) au sein 
de cette population jeune. La sévérité de la CR au diagnostic et l’antibioprophylaxie 
sont les deux facteurs associés à la survenue d’événements. Ces résultats sont en 
faveur de l’intérêt du diagnostic précoce, lorsque la valvulopathie est encore modérée, 
et de la poursuite du traitement antibiotique afin d’éviter les rechutes. Ceci plaide en 
faveur du dépistage systématique et de la mise en place de registres encadrant 
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l’administration d’antibioprophylaxie secondaire dans les pays où la CR demeure un 
problème de santé publique. 
 
5.5. Conclusions 
 
Les réulstats des trois études originales que constitue cette thèse apportent des 
résultats ayant un intérêt potentiel pour les actions de santé publique visant à contrôler 
le RAA et la CR en Nouvelle Calédonie et dans le Monde. Les méthodes issues des 
études à visée de recherche ne peuvent être transposées en campagnes de dépistage 
écho-guidées à l’échelle nationale. Le pronostic de la CR asymptomatique dépistée 
par échographie est bénin à moyen terme, quoique les lésions échographiques 
persistent dans la majorité des cas. La CR étant une maladie acquise, un dépistage 
ponctuel à un âge jeune (9-10 ans) ne permet pas de préjuger de l’absence de lésions à 
l’adolescence chez les populations à rsique. Une méthode de dépsitage par échoscopie 
à l’aide d’échographes de poche par des non-experts utilisant des critères 
diagnostiques adaptés pourrait avoir un intérêt dans les pays en voie de 
développement où la maladie demeure endémique. Enfin, les données 
épidémiologiques issues du dépistage échographique sont en accord avec celles de 
données hospitalières évaluant la CR symptomatique en Nouvelle Calédonie. Le 
diagnostic y est encore souvent porté à un stade tardif, révélé par des complications. 
La mortalité à 8 ans de la CR symptomatique sans complication initiale est basse mais 
la morbidité importante en Nouvelle Calédonie, pays où les patients ont accès aux 
interventions valvulaires.  
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